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LIGAND-INDUCED CONFORMATIONS OF  
EXTRACELLULAR LOOP 2 OF AT1R 
 
HAMIYET UNAL 
 
ABSTRACT 
 
Angiotensin II type 1 receptor (AT1R) is a G-protein coupled receptor (GPCR) 
and an important regulator of blood pressure. It is a target for drug development, because 
abnormalities in its function are linked to hypertension, cardiac hypertrophy and heart 
failure. AT1R is composed of seven transmembrane helices connected by three 
extracellular loops and three intracellular loops. The extracellular loop 2 (ECL2) of 
AT1R directly interacts with the ligands. This loop is targeted by autoantibodies that 
activate AT1R in several pathologies such as preeclampsia, malignant hypertension and 
vascular allograft rejection. Therefore, we proposed that the conformation of ECL2 in 
AT1R is differentially regulated upon binding to agonists and antagonists.  
 
We determined the conformation of the ECL2 of AT1R by reporter-cysteine 
accessibility mapping in different receptor states (i.e., empty, agonist-bound and 
antagonist-bound). We introduced cysteines at each position of ECL2 of a receptor 
surrogate lacking all non-essential cysteines and measured reaction of these with a 
cysteine-reactive biotin probe. The ability of biotinylated mutant receptors to react with a 
vi 
 
streptavidin-HRP-conjugated antibody was used as the basis for examining differences in 
accessibility.  
 
Two segments of ECL2 were accessible in the empty receptor, indicating an open 
conformation of ECL2. These segments were inaccessible in the ligand-bound states of 
the receptor. Using the accessibility constraint, we performed molecular dynamics 
simulation to predict ECL2 conformation in different states of the receptor. Analysis 
suggested that a ‘lid’ conformation of ECL2 was induced upon binding to both agonists 
and antagonists, but exposing different accessible segments delimited by a highly 
conserved disulfide bond between ECL2 and TMIII. We propose that the ligand-induced 
ECL2-lid is coupled to movements of transmembrane helices through the conserved 
disulfide bond to achieve the transition to the active state of the receptor.  
 
Our study reveals the ability of ECL2 to interact with diffusible ligands and adopt 
a ligand-specific ‘lid’ conformation. Distinct conformations induced by the agonist and 
the antagonist around the conserved disulfide bond suggest an important role for the 
disulfide bond in producing different functional states of the receptor. Dynamics of ECL2 
may regulate the fundamental process of receptor activation and pathophysiological 
processes involving GPCRs.  
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CHAPTER I 
INTRODUCTION 
 
1.1 G-Protein Coupled Receptors (GPCRs) 
1.1.1 General Features of GPCRs  
G-protein-coupled receptors (GPCRs) are seven-transmembrane helix proteins 
that are coupled to guanine nucleotide-binding proteins (G-proteins) upon activation by a      
specific ligand. GPCRs are the largest family of cell surface receptors, having a major 
role in signal transduction. They are ubiquitously expressed in eukaryotes, from yeast to 
human, and represent 2% of the genes in the human genome with approximately 1000 
members (Takeda et al, 2003). GPCRs convey extracellular signal across the cell 
membrane as a response to a diverse array of ligands including hormones, ions, 
neurotransmitters, proteins/peptides, fatty acids, small molecules and physical stimuli 
such as light, smell, taste and mechanical stretch (Lagerstrom and Schioth, 2008, 
Rosenbaum et al, 2009). GPCRs constitute a significant field of research due to their 
relevance to membrane biophysics, cell signaling, pharmacology, physiology, 
pathophysiology and drug discovery. 50% of all current human therapeutics is 
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targeted to GPCRs, which only constitutes a small fraction of known GPCRs. Therefore, 
there is an extensive search for new drugs that target GPCRs with high efficacy and 
specificity. Due to the relevance of GPCRs to drug discovery, understanding the roles of 
GPCR signaling in physiology and pathophysiology and delineating the structure-
function relationships of GPCRs have been a major focus of studies in receptor biology. 
     
GPCRs are transmembrane proteins with a common architecture (Fig 1.1 A) 
characterized by seven-transmembrane (TM) helices, connected by extracellular loops 
(ECL) and intracellular loops (ICL) (Lagerstrom and Schioth, 2008, Rosenbaum et al, 
2009). The N-terminal tail faces the extracellular region while, the C-terminal region is 
intracellular. When the GPCRs fold to a three-dimensional structure within the 
membrane, the TM helices forms an aqueous channel open to the extracellular space. 
This channel is filled with water molecules forming a ligand binding pocket, 20-30 Å 
deep in the TM domain (Fig. 1.1 B&C). Ligands bind to the receptor on the extracellular 
side. The rigid body movements of TM helices, with a length of 25-30 residues, transmits 
the signal to the intracellular loops which bind and activate the heterotrimeric G-protein. 
The intracellular loops, particularly the second and third loops, are the critical sites for G-
protein interaction. (Bockaert and Pin, 1999) The G-protein consists of an α-subunit, 
responsible for GTP/GDP binding and GTP hydrolysis, and a complex formed by β- and 
γ-subunits. The intracellular loops determine the specificity of a GPCR for a particular 
subtype of α-subunit of G-proteins such as Gαs, Gαi and Gαq. The intracellular loops of 
different GPCRs specifically interact with certain G-protein subtypes but, they also have 
a low affinity for other subtypes. Upon activation, the GDP of the G-protein is exchanged  
2
Figure 1.1. General configuration of GPCRs. A) Depiction of the secondary structure 
of a GPCR. B) Depiction of the three dimensional structure of a GPCR. C) Depiction of 
the ligand binding pocket of a typical family A GPCR. (from Ji et al, 1998) 
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with GTP which results in dissociation of the α and βγ subunits of the heterotrimeric 
protein. Dissociated Gα and Gβγ subunits further activates intracellular downstream 
effectors such as adenylyl cyclases and phospholipases which in turn affect the levels of 
second messengers such as cAMP and calcium. In addition to the classical second-
messenger mediated signaling pathways activated through G-protein coupling, recent 
studies have discovered a number of alternative signaling mechanisms that are related to 
diverse biological functions of these receptors (Pierce et al, 2002). GPCRs can also signal 
in a G-protein-independent manner, leading to activation of mitogen-activated protein 
kinase (MAPK) pathways (Miura et al, 2004). The cytoplasmic tail of GPCRs is target 
for agonist-induced posttranslational modifications such as phosphorylation and 
palmitoylation. The C-terminal tail of activated GPCRs is phosphorylated by G-protein-
coupled receptor kinases (GRKs). The phosphorylated C-terminal tail of a GPCR recruits 
intracellular proteins such as β-arrestin and leads to internalization followed by recycling 
or lysozomal degradation (Tan et al, 2004). Palmitoylation of some GPCRs at the 
cysteine residues, found in the C-terminal tail, creates a fourth loop which may regulate 
the phosphorylation and internalization (Resh, 2006).  
 
The assembly of GPCRs into dimers and oligomers adds an additional level of 
complexity to the mechanisms underlying the functioning of GPCRs. The ability of 
GPCRs to interact with various intracellular proteins that activate various signaling 
pathways provide a mechanism for physiological regulation of biological activity. 
Mechanisms for GPCR regulation occur during their biosynthesis by gene transcription, 
translation, and posttranslational processing or, during trafficking to the cell membrane. 
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Once the receptor is on the cell membrane, the regulatory mechanisms involve the 
process of GPCR desensitization and internalization, receptor recycling and lysosomal 
degradation.  
 
1.1.2 Classification and Evolution of GPCRs  
The gene repertoire of GPCRs extends from yeast to complex eukaryotic 
organisms including the nematodes, insects, plants, and mammals, indicating their 
evolutionary success (Fredriksson et al, 2003). GPCRs are not found in prokaryotes. 
Bacteriorhodopsin is a light-sensing seven transmembrane protein found in bacteria, 
which might have a common origin with GPCRs in eukaryotes. It is a proton pump 
involved in producing energy. However it is not a GPCR, does not couple to G-proteins, 
and does not have significant sequence homology to GPCRs (Okada and Palczewski, 
2001).  
 
Phylogenetic analysis classifies GPCRs into five families based on their sequence 
and structural similarities (Fredriksson et al, 2005). These families are Rhodopsin, 
Secretin, Adhesion, Frizzled/Taste2, and Glutamate families, known as the GRAFS 
classification system (Fig. 1.2). Surprisingly, there is minor sequence homology between 
different GPCRs families. In addition to lack of amino acid sequence conservation, there 
is variation in the length and function of their N-terminal and C-terminal domains and 
extracellular and intracellular loops. These types of variations give specific structural 
properties to different GPCRs. However, the sequence comparison within a particular 
receptor family shows some degree of sequence similarity. Sequence analysis within a 
5
Figure 1.2. Evolutionary tree of GPCRs in different species. Adapted from 
Fredriksson et al, 2005. 
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particular family reveals conservation of amino acids with similar residue type, rather 
than the sequence identity. Compared to N-terminal (7–595 amino acids) and C-terminal 
regions (12–359 amino acids), the size and sequence of TM domains (20–27 amino acids) 
are highly conserved, as well as the size of the loops (5–230 amino acids).  
 
Among GPCR families, the rhodopsin family is the largest and the most diverse, 
representing approximately 60% of the GPCR repertoire. The rhodopsin family is further 
divided into subgroups, based on ligand similarity, including opsins (rhodopsin etc.) 
amine receptors (muscarinic receptors, adrenoreceptors, dopamine receptor, serotonin 
receptor), peptide receptors (angiotensin receptor, bradykinin receptor, chemokine 
receptor, opioid receptor, etc.), glycoprotein binding receptors (follicle stimulating 
hormone receptor, thyrotropin receptor, etc.), olfactory receptors, and nucleotide like 
receptors (Fredriksson et al., 2003). The characteristic feature of the rhodopsin family is 
the presence of conserved amino acid sequences, such as the NPxxY motif at the end of 
TMVII, the DRY motif at the end of TMIII, and the conserved N residue in TMI. The 
presence of such motifs suggests common structural features and activation mechanisms. 
Most of the ligands for rhodopsin family GPCRs bind within a cavity formed by the TM 
helices (Baldwin, 1994). However, the ligand-binding domain in the glycoprotein binding 
receptor family is in the N-terminus.  
 
The receptors in other GPCR families, particularly in the adhesion family, have 
long N-terminal regions. The long N-terminus (200-280 amino acids) of adhesion family 
receptors are suggested to interact with other membrane bound proteins which provides 
7
cell-to-cell adhesion in a ligand independent manner. They have conserved sequence 
motifs within the N-terminus, such as epidermal growth factor (EGF)-like repeats, 
mucin-like regions, and conserved cysteine-rich motifs (Fredriksson et al, 2005). 
 
The secretin family of GPCRs also contains the ligand binding domains in their 
N-terminal region. These binding domains interact with large peptides with paracrine 
actions that share sequence similarity. The N-terminus (60-80 amino acids) contains 
conserved cysteine bridges that are likely to participate in ligand binding. Some examples 
of secretin family GPCRs are the calcitonin receptor, glucagon receptor and parathyroid 
hormone receptor (Fredriksson et al, 2005). 
 
The glutamate family GPCRs also has a long N-terminal region (280 to 580 
amino acids) with the ligand binding domain that interacts with small molecules such as 
glutamate, gamma-aminobutyric acid (GABA), calcium ions, and taste molecules. The N-
terminus forms a “Venus fly trap” structure with a cavity in which glutamate binds 
(Fredriksson et al, 2005). 
 
The frizzled family of GPCRs signals through glycoproteins called Wnt and 
mediates cell fate, proliferation, and polarity during development. The N-terminus (200 
amino acids) of the frizzled family of receptors contains conserved cysteines and 
participates in Wnt binding (Fredriksson et al, 2005). 
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1.1.3 Structural Features of GPCRs 
The structural knowledge of GPCRs has been obtained by the three dimensional 
crystal structure of a prototypical GPCR, bovine rhodopsin covalently bound to the 
inverse agonist 11-cis retinal (Palczewski et al, 2000), sequence alignment and molecular 
models based on the rhodopsin structure, and site-directed mutagenesis studies. 
Complementary biophysical approaches have been performed to understand the dynamic 
features of GPCRs that enable transition of signals triggered by ligand binding to 
intracellular proteins. (Hamm, 2001) These approaches include site-directed spin labeling 
(Yang et al, 1996, Farrens et al, 1996, Altenbach et al, 1996) and electron paramagnetic 
resonance (EPR), fluorescence spectroscopy (Loewen et al, 2001), substituted cysteine 
accessibility mapping, and nuclear magnetic resonance (NMR) spectroscopy (Ahuja et al, 
2009, Bokoch et al, 2010). All of these studies provided insight into the general 
configuration of GPCRs, positioning of the TM domains, and residues participating in 
ligand binding and interaction with intracellular signaling proteins. These studies 
improved our understanding of molecular mechanism of GPCR activation and signaling. 
 
These studies have been followed by the high resolution inactive structures of 
several other GPCRs, including the human β2 adrenergic receptor bound to the inverse 
agonists carazolol and timolol (Cherezov et al, 2007, Rasmussen et al, 2007), the avian β1 
adrenergic receptor bound to the antagonist cyanopindolol (Warne et al, 2008), and the 
human A2A-adenosine receptor bound to the antagonist ZM241385 (Jaakola et al, 2008). 
Furthermore, the structures of the active, unliganded opsin (Park et al, 2008) and opsin 
bound to the C-terminal sequence of the G protein, transducin (Scheerer et al, 2008) have 
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been solved and provided information about the conformational changes associated with 
active state of rhodopsin. There are both similarities and differences among the four 
known inactive structures of GPCRs. The extracellular domains, including the ends of the 
TM helices and the extracellular loops, show the greatest difference which may allow the 
recognition of a wide spectrum of ligands. (Rosenbaum et al, 2009) 
 
The ligand binding domains of these rhodopsin family GPCRs share remarkable 
similarity. However, between GPCR families, the ligand binding domains show diversity. 
The ligand binding pocket for small molecular weight ligands is within the hydrophobic 
core formed by the TM helices whereas the ligand binding sites for larger peptides 
include the N terminus and the extracellular loops, as well (Perez and Karnik, 2005). 
 
The conserved structural features of GPCRs suggest a common molecular 
mechanism for ligand-induced activation among different families of GPCRs (Gether, 
2000). The previous studies of rhodopsin, a prototypical GPCR, provide useful 
knowledge on ligand-receptor interactions of TM and intracellular domains. However, 
the structure-function relationships of extracellular domains have not been well 
understood. Although the interactions with TM helices are recognized as the major factor 
for activation of GPCRs, accumulating evidence has revealed a new and unanticipated 
role for the extracellular loops (ECLs) in the functioning of GPCRs (Karnik et al, 2003). 
Compared to the variable structure of N-terminus, the lengths of all other ECLs are 
highly conserved among GPCRs, which implies that a conserved function is mediated by 
the extracellular domain. The significance of the extracellular domains for ligand binding 
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and receptor activation has been shown for the majority of GPCRs from different 
families. For the rhodopsin family GPCRs, the ligand binding site is found deep within 
the seven transmembrane bundle. However, small peptide ligands make contact with the 
ECLs while entering the TM core. In the secretin family of GPCRs which are 
characterized by longer N-terminal domains, ECLs contribute to receptor activation 
altough the ligand binds to the N-terminal domain. The interaction of ligand with ECLs is 
crucial for the TM domains to activate the glutamate family of receptors. The ligand-
induced activation of the other two GPCR families, adhesion and frizzled receptors has 
been shown to be impaired by the mutations in ECLs. These observations suggest a 
conserved role for the extracellular domains throughout the GPCR superfamily (Karnik et 
al, 2003). 
 
In addition, the extracellular loop 2 (ECL2) is characterized by a highly conserved 
disulfide bond linking the loop to the TMIII in more than 90% of GPCRs. Disruption of 
this disulfide linkage directly affects receptor folding and function in most GPCRs, 
indicating an important role for the disulfide bond and ECL2 in receptor structure-
function relationships (Karnik et al, 2003). The ECL2 attracted additional interest upon 
the elucidation of the high-resolution crystal structure of bovine rhodopsin, the first 
structure of a mammalian GPCR. In this structure, the loop makes extensive contacts 
with the other extracellular domains and adopts an anti-parallel β-hairpin structure that 
projects into the TM core, covering the retinal binding site (Palczewski et al, 2000). On 
the other hand, unlike the buried β-hairpin structure in rhodopsin, the ECL2 in the 
recently solved structures of β2 and β1 adrenergic receptors has an extra helix and an 
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intraloop disulfide bond in addition to the conserved disulfide bond between ECL2 and 
TMIII (Cherezov et al, 2007, Rasmussen et al, 2007, Warne et al, 2008). Despite this 
conformational difference, different GPCR structures predict that ECL2 is a part of the 
ligand binding pocket and has a vital role in receptor function.  
        
1.1.4 Activation of GPCRs  
Transmembrane signal transduction during the activation of GPCRs adheres to a 
common molecular mechanism (Karnik et al, 2003). Binding of activating ligands to a 
GPCR induces rigid-body movements of TM helices which facilitate G-protein 
activation, leading to cytoplasmic signal transduction. Elucidating the nature of the 
conformational changes in GPCRs that are induced by different types of ligands is critical 
to understand the molecular mechanism of GPCR signaling. GPCRs show some level of 
basal activity in the absence of an agonist and activate the G-protein in an agonist 
independent manner. This basal activity can be modulated by different types of ligands. 
Agonists are ligands that fully activate the receptor, whereas partial agonists induce 
submaximal activation of the G-protein, even at saturating concentrations. Inverse 
agonists reduce the basal activity and antagonists compete with the other ligands without 
affecting on basal activity (Kiya et al, 2010). 
 
Different models have been proposed to explain GPCR activation upon agonist 
binding (Perez & Karnik, 2005). The “bimodal switch model” simply proposes that the 
receptor exists in equilibrium between the inactive state and the active state. The level of 
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basal receptor activity is determined by the equilibrium between these two states in the 
absence of agonists. The binding of ligand changes the equilibrium between active and 
inactive states.  
 
A more complex model suggests that constraining interactions keep the receptor 
in an inactive conformation. Upon activation by agonists or activating mutations, these 
interactions are released, exposing the key residues for the G-protein interaction. The 
unbound receptor can assume several intermediate conformational states with different 
affinities for the G-protein. Each conformation can selectively interact with a ligand, 
leading to a specific intracellular signaling outcome. The inverse agonist stabilizes the 
inactive state by increasing the number of constraining interactions, whereas the agonist 
stabilizes the active state by releasing such interactions. Partial agonists may stabilize an 
intermediate state that has lower affinity for the G-protein. G-proteins may also interact 
with the empty receptor and stabilize the receptor in a different intermediate state that 
increases the affinity for agonist. The modulation of basal activity of GPCRs by different 
types of ligands indicates the dynamic nature and inherent flexibility of GPCRs and the 
existence of multiple conformational states in the absence of ligands (Perez & Karnik, 
2005). Evidence suggests that during agonist binding and activation, the receptor 
undergoes a series of intermediate conformations through interactions formed between 
the receptor and the agonist, disruption of constraining intramolecular interactions that 
stabilize the basal state of the receptor and rearrangement of a new set of intramolecular 
interactions (Kobilka and Deupi, 2007, Ahuja and Smith, 2009). The flexibility of 
GPCRs is essential for their physiological functions (Kobilka and Deupi, 2007). A better 
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understanding of the dynamic nature of GPCRs might facilitate structure based drug 
discovery. 
 
The fundamental question of the mechanism of GPCR activation is, what are the 
conformational changes induced by agonist which are then propagated to the cytoplasmic 
domain that couples to the G-protein. The recent crystal structures of active states of 
opsin (Park et al, 2008, Scheerer et al, 2008) and solid-state nuclear magnetic resonance 
(NMR) studies provide insight into the transmembrane helix rearrangements upon agonist 
binding. Ahuja et al (2009) has shown that conformational changes upon light activation 
of rhodopsin includes movement of TM helices that disrupts a hydrogen-bond network 
between ECL2 and the extracellular ends of TMIV, TMV and TMVI, displacing the 
ECL2 during rhodopsin activation. Using NMR spectroscopy, Bokoch et al (2010) 
reported that ECL2 of the β2-adrenergic receptor is in distinct conformations depending 
on the type of the ligand bound to the receptor, and identified ECL2 as a direct reporter of 
the receptor’s active state. 
 
1.1.5 GPCRs and Disease  
Coordination of signaling networks activated by GPCRs ensures proper 
functioning of biological systems. GPCRs have significant roles in the regulation of 
physiology. GPCR related defects have been shown to cause a wide range of genetic and 
somatic diseases including cardiovascular diseases and cancer (Paul et al, 2007). 
Mutations observed in GPCRs may cause deficiency in cell surface expression or ligand 
binding, generation of abnormal signals, constitutive activation, or uncontrolled 
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desensitization and internalization, all of which may lead to disease conditions. These 
mutations have been identified particularly in GPCRs that mediate the actions of sensory 
signals, hormones and neurotransmitters. Some examples are rhodopsin, gonadotrophin 
receptor, calcium sensing receptor, angiotensin receptors and vasopressin receptor. (Table 
I.I) Some beneficial mutations of GPCRs have also been reported, such as a mutation in a 
chemokine (CCR5) receptor. CCR5 receptor is a co-receptor for human 
immunodeficiency virus (HIV). A mutation in this receptor prevents the interaction of 
HIV with target cells, preventing HIV infection. (Galvani and Novembre, 2005) Diseases 
related to mutations in GPCRs are not common and observed in less than 1% of the 
human population. Some genetic variations in GPCRs, including single nucleotide 
polymorphisms (SNP), are also identified as contributors to diseases (Paul et al, 2007). 
Disease-related polymorphisms have been identified in angiotensin II type 1 and type 2 
receptors (Baudin, 2005) and chemokine receptor (Insel et al, 2007). Many other diseases 
are caused by malfunctioning of GPCR signaling in cellular systems. Systemic disorders 
such as cardiovascular diseases (hypertension, heart failure), metabolic diseases 
(diabetes, obesity, kidney damage) respiratory diseases (asthma), and degenerative 
diseases (Parkinson’s disease) are related to loss of regulation of GPCR signaling. As a 
therapeutic approach, agonists and antagonists of GPCR have been proved useful for 
treatment of these diseases. Development of more specific and effective drugs is the 
major goal in the field of GPCR research. 
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Table I.I Examples of disease causing mutations in GPCRs. Adapted from Paul et al, 
2007. 
 
Receptor/Gene name Mutation Disease
Calcium-Sensing/CaSR Multiple (e.g. Arg185Gln) Autosomal Dominant Hypocalcemia, Sporadic and Familial Hypoparathyroidism 
CXCR4 
 Multiple (e.g. Ser338X) WHIM syndrome 
Endothelin receptor 
B/EDNRB Multiple (e.g. Trp276Cys) Hirschsprung’s disease 
Follicle-stimulating 
hormone/FSHR Multiple (e.g. Ala189Val) Female infertility 
N-formyl-peptide 
receptor/FPR1 Phe110Ser, Cys126Trp Juvenile periodontitis 
Frizzled/FZD4 
 Multiple (e.g. Arg417Gln) Familial exudative vitreoretinopathy  
Gonadotropin-releasing 
hormone/GNRHR Multiple (e.g. Arg262Gln) Hypogonadotropic hypogonadism  
GPR54/GPR54 
 Multiple (e.g. Cys223Arg) Hypogonadotropic hypogonadism  
GPR56/GPR56 
 Multiple (e.g. Cys223Arg) Bilateral frontoparietal polymicrogyria  
vGPCR/KSHV-GPCR 
 (constitutively active) Kaposi’s sarcoma  
Relaxin family peptide 
receptor 2/LGR8 Multiple (e.g. Thr222Pro) Cryptorchidism 
MASS1 Multiple (e.g. Ser2652X)) Usher syndrome  Febrile seizures  
Melanocortin/MC4R 
 Multiple (e.g. Pro78Leu) Dominant and recessive obesity 
Rhodopsin/RHO 
 Multiple (e.g. Pro23His) Retinitis pigmentosa  
Vasopressin receptor/AVPR2 
 Multiple (e.g. Arg113Trp) Nephrogenic diabetes insipidus 
Luteinizing hormone 
receptor/LHR Gly578Asp Familial male precocious puberty 
Angiotensin II type 2 
receptor/ AT2R Multiple (e.g. Arg324Gln) X-linked mental retardation  
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1.1.6 Drug Discovery 
The molecular models of GPCRs have been extensively used for in silico 
screening and identification of novel small-molecule ligands (Karnik et al, 2003). The 
availability of crystal structures of several GPCRs has enabled more precise screening for 
those GPCRs.  
 
Three different types of therapeutic agents targeting GPCRs, including orphan 
GPCRs, have been identified by virtual screening of synthetic chemical libraries and 
natural compounds. First, novel agonists that activate GPCRs have been particularly 
useful for orphan GPCRs whose endogenous ligands are not known. Second, antagonists 
are also very useful for elucidating the cellular roles of orphan GPCRs. They are highly 
important for treatment of diseases related to GPCR overactivity for which we do not 
have an effective therapy. Third, inverse agonists can target the constitutively active 
mutants of GPCRs which can not be effectively inhibited by antagonists. The inverse 
agonists are also useful for characterization of orphan GPCRs. There are a few examples 
of other types of novel therapeutic agents that specifically target heterodimers of some 
GPCRs. An example is a drug specifically designed against the µ-opioid/δ-opioid 
receptor heterodimer (Daniels et al, 2005). 
 
1.2 Angiotensin II Type 1 Receptor (AT1R) 
1.2.1 Renin Angiotensin System 
The renin angiotensin system (RAS) plays a critical role in maintaining the salt-
water balance as well as blood pressure. The RAS is activated in response to decreased 
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plasma sodium and fluid volume, resulting in stimulation of the renin enzyme secretion 
from juxtaglomerular cells of the kidneys (Fig. 1.3). The enzyme renin cleaves 
circulating angiotensinogen to angiotensin I (Ang I), which is a decapeptide representing 
the N-terminus of angiotensinogen. The C-terminal dipeptide of Ang I is hydrolyzed by a 
carboxypeptidase, angiotensin converting enzyme (ACE), to produce Ang II. It is an 
extremely potent vasoconstrictor hormone and acts on the adrenal glands to stimulate the 
release of aldosterone, increasing blood pressure. Ang II interacts with two types of G-
protein coupled receptors to elicit a cellular response; angiotensin II type 1 (AT1R) and 
angiotensin II type 2 (AT2R) receptors (Gasparo et al, 2000). 
 
The major cardiovascular effects associated with Ang II are mediated through AT1R, 
such as vasoconstriction, aldosterone and vasopressin secretion, and activation of 
sympathetic nervous system (Dinh et al, 2001). The physiological effects of AT2R 
remain to be discovered. AT2R is known to antagonize the AT1R effects and possibly 
plays role in several AT1R-independent biological processes such as apoptosis and 
cellular differentiation (Table I.II). In contrast to global expression of AT1R in many 
tissues, AT2R is only expressed during fetal development. The vital functions of AT1R 
have also been indicated by the severe effect of complete ablation of AGT1R gene. 
However, AGTR2 gene depletion does not show defective phenotypes, except for a slight 
increase in the blood pressure (Oliverio et al, 1998). Moreover, AT1R mutations are very 
rare in populations, whereas AT2R mutations can be tolerated. Over activity of RAS is 
related to many diseases including hypertension, heart-failure, diabetes, renal and 
inflammatory diseases (Teerlink, 1996). The hypertrophic effects of RAS are elicited by 
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Figure 1.3. The Renin-Angiotensin system (RAS). Decreased blood pressure stimulates 
renin secretion from kidneys. Renin cleaves angiotensinogen into Ang I, which is in turn 
cleaved by ACE to produce the octapeptide Ang II. Ang II is the major active peptide of 
RAS that regulates blood pressure through vasoconstriction and stimulation of 
aldosterone and vasopressin (ADH) release. Ang II may also give rise to pathological 
conditions such as cardiac and vascular hypertrophy and end-organ damage.  
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Table I.II. Differential effects of AT1R and AT2R stimulation by Ang II. Adapted 
from Siverstein and Ram, 2005 
 
AT1R AT2R 
Increased vasoconstriction Regulation of fetal tissue development 
Increased aldosterone synthesis & secretion Regulation of cell growth and proliferation 
Increased tubular sodium reabsorption  Regulation of extracellular matrix composition 
Increased vasopressin secretion Regulation of cell differentiation 
Increased cardiac hypertrophy Regulation of apoptosis 
Increased cardiac contractility Regulation of left ventricular remodeling 
Increased vascular smooth muscle proliferation Increased neuronal regeneration 
Increased noradrenergic activity Vasodilation  
Cell growth and proliferation Antiproliferation 
20
the binding of Ang II to the AT1R. Genetic manipulations of the mouse AGTR1 gene 
significantly alter blood pressure as well as cardiac and renal functions (Paradis et al, 
2000). Drugs targeting AT1R can effectively lower blood pressure, whereas drugs 
targeting AT2R do not have an effect on RAS induced pathologies.  
 
1.2.2 Significance of AT1R  
The AT1R is a 359 amino acid peptide hormone GPCR which belongs to the 
rhodopsin family.  It is expressed in liver, kidney, aorta, lung, uterus, ovary, spleen, heart, 
adrenal, and vascular smooth muscles. Upon Ang II binding, AT1R productively couples 
to the G-protein, Gαq/11, which leads to the activation of phospholipase C (PLC), 
producing inositol-1, 4, 5-triphosphate (IP3) and Diacylglycerol (DAG). Calcium 
mobilization results in smooth muscle cell contraction, which is associated with increased 
blood pressure (Fig. 1.4). The intracellular downstream signaling involves the 
phosphorylation of extracellular signal regulated kinases (ERK1/2) in cells (Fig. 1.4). In 
addition, the AT1R activates tyrosine kinases such as Janus Kinase (JAK) and epidermal 
growth factor receptor (EGFR) (Gasparo et al, 2000, Miura et al, 2004). 
 
AT1R is an important target for drug development, because abnormal AT1R function 
causes hypertension, water-electrolyte imbalance, cardiac hypertrophy and heart failure, 
which are the main causes of death in the Western world. The importance of AT1R 
activation has been demonstrated in all of these diseases. ACE inhibitors and AT1R 
antagonists, also known as AT1R blockers (ARBs), are used effectively as therapeutic 
agents to lower blood pressure and to prevent cardiac and vascular hypertrophy       
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Figure 1.4. The major AT1R signal transduction pathway. Ang II binding activates 
the Gq coupled signaling pathway leading to activation of PLC, which results in calcium 
moblilization and activation of MAPK. 
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(Siverstein and Ram, 2005, Doulton et al, 2005). ACE inhibitors compete with ACE to 
reduce Ang II production, whereas, ARBs compete with Ang II for binding to AT1R. The 
ARBs are well tolerated with fewer side effects than ACE inhibitors. ARBs completely 
block actions of Ang II on the AT1R, irrespective of whether Ang II is generated 
systemically or by non-ACE mediated pathways. Several ARBs available for the 
treatment of RAS associated disorders are losartan, for treatment of hypertension and 
hypertrophy, irbesartan, for treatment of diabetic nephropathy, and valsartan, for 
treatment of heart failure in people who cannot tolerate ACE inhibitors. Understanding 
the activation mechanism of AT1R is very important for development of more effective 
therapeutic agents.  
   
1.2.3 Ang II binding and Activation of AT1R 
Modification of Ang II, site-directed mutagenesis and crosslinking studies established 
the interactions between Ang II (DRVYIHPF) and AT1R (Fig. 1.5). The ligand binding 
pocket formed by the hydrophilic TM domain residues is shown in Fig. 1.6 A. There are 
two salt bridges, one between Arg2 of Ang II and Asp281 of AT1R and second between 
the carboxyl group of Ang II and Lys199 of AT1R (Yamano et al, 1992, Noda et al, 1995, 
Feng et al, 1995, Lefkowitz et al, 1993). The Asp1 of Ang II forms an ion pair with His183 
in the ECL2 of AT1R (Feng et al, 1995). The aromatic stacking interactions between 
Phe8 of Ang II and His256 of AT1R (Noda et al, 1995) and between Tyr4 of Ang II and 
Asn111 of AT1R (Noda et al, 1996, Miura et al, 1998, Miura et al, 1999) were shown to 
be critical not only for ligand docking but also for receptor activation (Fig. 1.6 B). 
Crosslinking has shown two additional interactions, one between Phe8 of Ang II and 
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Figure 1.5. Specific interactions of AT1R with Ang II and losartan. Secondary 
structure model of rat AT1R, showing the interactions of AT1R with Ang II, previously mapped 
by site directed mutagenesis (blue) and cross linking experiments (red). The AT1R residues 
interacting with losartan are shown in yellow. 
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Figure 1.6. Ang II binding to AT1R. A) Orientation of hydrophobic (magenta) and 
hydrophilic (cyan) side chains in the rat AT1R. Both membrane plane view and 
extracellular view is shown. (from Gogonea et al, 2006) B) The predicted hormone-
binding site. Both membrane plane view and extracellular view is shown. Ang II in the 
binding site is shown in space filling model, with Phe8 (magenta), Tyr4 (orange) and other 
side chains (green) (from Gogonea et al, 2006). C) Replacement of water molecules in 
the ligand binding pocket in the empty state of the AT1R by Tyr4 side chain of Ang II, 
interacting with Asn111 in the active state of AT1R, as shown (from Husain and Graham, 
2000). 
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Phe293 and Asn294 in TMVII of AT1R (Perodin et al, 2002), the other between Val3 of 
Ang II and Ile172 in the ECL2 region of the AT1R (Boucard et al, 2000). Thus, the 
hydrophobic C-terminal region of Ang II appears to enter the TM core of the receptor. 
The N-terminal region of Ang II is positioned towards the extracellular region of the 
AT1R.  
 
Several Ang II analogs have been generated by modification of Ang II side chains 
to evaluate the effects on ligand binding and receptor activation (Miura and Karnik, 
1999a). Ligand modification led to the identification of agonists, partial agonists and 
antagonists. For example, modification of either Tyr4 or Phe8 side chains of Ang II 
converts the agonist function into an antagonist function (Samanen et al, 1989). The 
effect of substitutions of Tyr4 or Phe8 side chains on receptor binding and activation has 
been further investigated by Miura et al (1999b). The aromatic side chains of these 
residues have been shown to be critical switches for G-protein activation (Fig. 1.6 C). 
Several other analogs retained partial agonist function. For example, [Ile4, Ile8] Ang II 
functions as a selective ligand, which does not lead to receptor internalization and 
stimulates β-arrestin dependent activation of ERK1/2 phosphorylation independent of Gq 
(Feng et al, 1998). The discovery of non-peptide Ang II antagonists and derivatives has 
significant therapeutic value. These antagonists have a structural pharmacophore similar 
to Ang II which enables them to compete with Ang II for binding to AT1R and to 
displace bound Ang II from the AT1R (Fig. 1.7 A). Losartan is a surmountable antagonist 
of AT1R which can be displaced by Ang II; however, carboxylated derivatives of 
losartan such as EXP3174, candesartan and irbesartan are insurmountable inhibitors. The 
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Figure 1.7. Chemical structures of the Ang II and AT1R non-peptide antagonists. A) 
Ang II and losartan pharmacophores (from Noda et al, 1995). B) Chemical structures of 
EXP3174, candesartan, and olmesartan. All compounds have biphenyltetrazole and 
imidazole groups. EXP3174, candesartan, and olmesartan, but not losartan, have a 
carboxyl group. Only olmesartan has a hydroxyl group (from Miura et al, 2006). 
 
A 
 
B 
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carboxylate group of these inhibitors provide an additional interaction with Gln257 of 
AT1R (Fig. 1.7 B) (Vanderheyden et al, 2000, Takezako et al, 2004). The structure of 
non-peptide antagonists mimics the contact points of Ang II side chains, and their binding 
sites overlap with the Ang II binding pocket in AT1R as shown by mutagenesis and 
crosslinking experiments (Yamano et al, 1992, Noda et al, 1995, Ji et al, 1995). For 
example, Lys199 of AT1R forms a salt bridge interaction with both the carboxyl group of 
Ang II and the tetrazole group of losartan (Fig. 1.8). 
  
Upon Ang II binding, activation of AT1R is shown to be associated with 
movements of TMII, TMIII, TMV, TMVI and TMVII (Fig 1.9) which is probably 
conserved in rhodopsin family GPCRs (Miura et al, 2002&2003, Boucard et al,2003, 
Martin et al, 2004 & 2007, Domazet et al, 2009). The disulfide bond linking TMIII and 
ECL2 is highly conserved in more than 90% of GPCRs and has been suggested to have a 
role in coupling the movements of TM helices to the ECL2 during receptor activation 
(Karnik et al, 2003). Whether the ECLs play any role in the transition from inactive to 
active state is not known. The role of ECLs in regulating the actions of agonists and 
antagonists has not been studied in any GPCR.  
 
           We proposed a model of GPCR activation that involves the movement of ECL2, 
which results in the movements of transmembrane domains (Karnik et al, 2003). Our 
model is based on the findings that (i) the length of ECL2 in GPCRs is conserved; (ii) 
electrostatic and hydrophobic interactions between different TM helices and ECL2 are 
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Figure 1.8. Overlapping binding pockets of Ang II and losartan. A) Experimentally 
mapped Ang II binding residues. B) Overlap of Ang II (red) and losartan (yellow) 
interacting residues. 
 
A)                                                                                      B) 
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Figure 1.9. Activation of AT1R. The transmembrane domains, TMII, TMIII, TMV, 
TMVI and TMVII, that undergo conformational change upon AT1R activation are shown 
in box. The highly conserved disulfide bond between TMIII and ECL2 is shown in 
yellow.  
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predicted in almost all GPCR models; (iii) a highly conserved disulfide bond links the 
ECL2 to TM3 in 92% of GPCRs, and this disulfide bond is required for the structural 
integrity and function in GPCRs examined; and finally (iv) the available crystal structures 
of GPCRs confirmed the interaction of ECL2 with TM domains and the ligand.  
 
Our proposal is further supported by observations reported by other investigators. 
These studies suggested significant interaction of ECL2 with Ang II and TM-helices. 
Two ECL2 residues, Ile172 and His183, have been shown by ligand cross linking and 
mutagenesis to directly interact with Ang II (Feng et al, 1995, Boucard et al, 2000). 
Mutagenesis of Glu173 in ECL2 leads to increased sensitivity to a partial agonist, 
CGP42112A, implying that Glu173 chain imposes a constraint for activation in the 
absence of ligand (Parnot et al, 2000). In addition, mutational studies in our laboratory 
indicate that Phe182 in ECL2 is quite important for antagonist binding (unpublished 
observations). Recently, AT1R activating antibodies directed against ECL2 were found in 
preeclamptic patients (Wallukat et al, 1999, Zhou et al, 2008) and patients with refractory 
vascular allograft rejection (Dragun et al, 2005). This suggests that ECL2 plays a role in 
governing the active state of the AT1R. Therefore, interactions of the ECL2 with TM 
domains may be important to guide ligands to the binding pocket and to regulate the 
ligand dependent activation of the receptor.  
 
1.3 The Extracellular Loop 2 in other GPCRs 
Crystallographic structures and accumulating structure-function studies suggest 
an unanticipated canonical role for ECL2 in ligand-induced activation of GPCRs. ECL2 
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in the prototypical GPCR, bovine rhodopsin (Fig. 1.10 A), adopts a β-hairpin structure 
that projects into the site of covalently bound retinal as ‘a stable lid’ directly interacting 
with the ligand (Palczewski et al, 2000, Park et al, 2008). Upon light activation ECL2 
moves away (Ahuja et al, 2009). Absence of a similar ‘lid’ in the recently solved 
structures of GPCRs suggests that a path for diffusible ligands to the binding pocket may 
be a specialization that evolved in other GPCRs. The ECL2 in β2 and β1 adrenergic 
receptors (Fig. 1.10 B & C) has an α-helical conformation stabilized by an intra-loop 
disulfide bond (Cherezov et al 2007, Warne et al, 2008). The ECL2 of A2A adenosine 
receptor (Fig. 1.10 D) with three disulfide bonds is unstructured (Jaakola et al, 2008). 
Despite these variations, all GPCR structures predict that ECL2 is a part of the ligand 
binding pocket. ECL2 makes direct contacts with bound inverse agonist, 11-cis-retinal in 
rhodopsin (Ser186 to Ile189, Glu181 and Tyr191), the antagonist cyanopindolol in β1 
adrenergic receptor (Thr203 and Phe201), the inverse agonist carazolol in β2 adrenergic 
receptor (Phe193) and the antagonist ZM241385 in A2A adenosine receptor (Phe168 and 
Glu169). Positioned at the entrance to the binding cavity, ECL2 may regulate the access of 
ligands and receptor activation in rhodopsin-like and other GPCR families (Bourne and 
Meng, 2000).  
 
The contribution of ECL2 in ligand binding and receptor activation has been shown 
for many GPCRs such as dopamine D2 receptor (Shi and Javitch, 2004), the adenosine 
A2A receptor (Jeongho et al, 1995), the M2 and M3 muscarinic acetylcholine receptor 
(Anu et al, 2004, Scarselli et al, 2007), adrenergic receptors (Zhao et al, 1996) and the 
histamine H1 receptor (Andrea et al, 2008). Importantly, some mutations on the ECL2 
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Figure 1.10. The ECL2 structures in crystal structures of GPCRs. A) ECL2 structure 
in Rhodopsin (from Cherezov et al, 2007). B) ECL2 structure in β2 adrenergic receptor 
(from Cherezov et al, 2007). C) ECL2 structure in β1 adrenergic receptor (from Warne et 
al, 2008). D) ECL2 structure in A2A adenosine receptor (from Jaakola et al, 2008). 
Disulfide bonds are shown in yellow. 
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led to constitutively active mutants in several GPCRs such as thyrotropin (TSH) receptor 
(Duprez et al, 1997) and complement C5A receptor (Klco et al, 2005), indicating that the 
ECL2 stabilizes the inactive conformation of these receptors. Importantly, receptor-
activating auto-antibodies against the ECL2 regions have been discovered in several 
human pathologies related to muscarinic receptors (Borda et al, 2004), β1 and β2 
adrenergic receptors (Magnusson et al, 1994, Lebesgue et al, 1998) and the bradykinin 
B2 receptor (Abdalla et al, 1995). Therefore, it is very important to study the structure of 
ECL2 in detail.  
 
Accumulating evidence suggests that the extracellular domain of AT1R plays a 
critical role in guiding Ang II and ARBs to bind to TM helices, but the molecular details 
are unclear. Based on molecular modeling and dynamic simulation studies, the AT1R 
structure differs from both rhodopsin and adrenergic receptors in several key aspects. 
Unlike rhodopsin which has covalently attached ligand, the AT1R has a diffusible ligand 
similar to the ligand of adrenergic receptors. AT1R is different from the adrenergic 
receptors due to the absence of additional intraloop disulfide bond. Therefore, AT1R may 
have a different mechanism of structural stabilization. Molecular dynamic simulation 
studies performed on the AT1R model predicted significant movement of ECL2, which is 
seen in open and closed conformational states. Thus, ECL2 is likely a pivotal structural 
element in generating different conformational states of AT1R, but the role it plays in 
reversible binding of ligands is unknown.  
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1.4 Significance of Current Work 
Evidence based on both biochemical studies and molecular modeling of AT1R 
suggests a critical role for ECL2 of AT1R in fundamental processes of ligand-mediated 
activation and inhibition of the receptor. Elucidating the conformational regulation of 
ECL2 by different types of ligands may help us dissect the pathophysiological processes 
mediated by AT1R. In this study, we examine the conformation of ECL2 of the AT1R 
specifically in basal, Ang II-bound and ARB-bound states by reporter-cysteine 
accessibility mapping (RCAM). RCAM analysis allows us to systematically map the 
surface accessibility of residues in a particular region of the receptor. RCAM involves 
site-directed mutagenesis to introduce cysteine residues at selected positions within the 
protein (Akabas et al, 1992). The reactivity of the introduced cysteines toward 
hydrophilic, thiol specific, alkylating reagents is the basis for determining their surface 
accessibility. The MTS reagents selectively and rapidly react with thiols (sulfhydryls) of 
water accessible cysteines. The reactivity of MTS reagents with a cysteine in the water 
accessible surface of a protein is much faster than one in the membrane or the protein 
interior. Thus, RCAM can give information on whether a cysteine at a particular position 
is buried or exposed (Fig. 1.11).  
 
Our accessibility mapping analysis of ECL2 of AT1R in different states of the 
receptor has indicated a ligand-induced conformational change in the ECL2. The highly 
accessible ECL2 of AT1R is rendered inaccessible upon binding to agonist and 
antagonist. Molecular dynamic simulations based on the accessibility constraint reveal an 
open conformation of ECL2 in the empty receptor that may facilitate capture of Ang II, 
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Figure 1.11. Schematic representation of ligand interference and ligand protection 
assay. 
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losartan and autoantibodies. A lid conformation of ECL2 is shown in both Ang II- and 
losartan-bound states. The ligand-induced lid conformation of ECL2 may slow down the 
dissociation of ligands and prolong the bound conformation. Conformational dynamics of 
ECL2 may regulate ligand mediated processes in AT1R. These dynamic studies are 
essential to improve remedies targeting AT1R for treatment of hypertension, heart failure 
and end organ damage due to high blood pressure. 
 
Our results have shown two different conformations of ECL2, open and closed 
conformations, where the open conformation seems ideal for facilitating autoantibody 
binding to AT1R. Autoantibodies have been shown to activate AT1R in several diseases, 
including preeclampsia and vascular allograft rejection (Liao et al, 2002, Dragun et al, 
2005, Zhou et al, 2008). Haptens specific for the open conformation of ECL2 can be 
designed to prevent autoantibody interaction with the AT1R and block the immune 
response against these autoantibodies in patients with these diseases.  
 
Our findings are significant in the context of the whole GPCR family of proteins. 
The ligand induced conformational changes of ECL2 shown in AT1R, which is a 
rhodopsin family GPCR, might have useful implications for other GPCR families, such 
as adhesion family GPCRs, for which there are no available antagonists. Novel agents or 
modifications could be developed to disrupt interaction of ECL2 with their long N-
terminal tails as a mechanism to inactivate these GPCRs. 
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Specific conformational changes induced by agonist and antagonist binding 
provides an experimental basis for further analysis of the effects of  various ARBs on 
AT1R dynamics and will aid in determining the high-resolution crystal structure of an 
ARB-bound AT1R.  
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Construction of Plasmids 
The hemagglutinin (HA)-tagged AT1R gene was cloned into the shuttle 
expression vector, pMT3, which contains unique EcoR1 and Not1 restriction sites (Fig. 
2.1 A). The synthetic rat AT1R gene is flanked by EcoR1 restriction site on the 5’ end 
and Not1 restriction site on the 3’ end. N-terminal HA epitope tag was introduced at the 
5’ end of the gene by polymerase chain reaction (PCR) amplification in the presence of 
FailSafe enzyme (Epicentre Biotechnologies, WI) using 10 pmol/µl of EcoR1-HA sense 
primer and 10 pmol/µl of Not1 antisense primer (Fig. 2.1 B). The sequence was 
confirmed by automated DNA sequencing (Fig. 2.2).  
 
CYS¯AT1R was generated by PCR mutagenesis as described previously (Miura 
et al, 2002 & Miura et al, 2003). Briefly, single residue mutations were introduced by 
mismatched primer method and combined with PCR amplification. Primers were 
designed to change cysteine residues at positions 76, 121, 144, 289, 296 and 355 into 
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Figure 2.1. Cloning of HA-AT1R gene in pMT3 expression vector. A) Schematic 
representation of pMT3 cloning vector. SV40, origin of replication; AdMLP, adenovirus 
major late promoter; TPL, tripartite leader sequence; IVN, intervening sequence; EcoR1-
Not1, cloning sites for expression; DHFR, dihydrofolate reductase promoter; VA1, 
adenoviral VA1 gene; pBR-ori1, origin of replication; AmpR; ampicillin resistance. B) 
Schematic representation of cloning of PCR amplified HA-AT1R gene into pMT3 vector. 
Primers used for PCR amplification are EcoR1-HA sense primer “CGGGAATTCGCCA 
CCATGTACCCATACGACGTCCCAGACTACGCGGCCCTTAACTCTTCT” and 
Not1 antisense primer “CCCCCGCGGCCGCCTATTAAGCTGGAGCAACTTG”. 
Template used was pcDNA3-AT1R. The parameters used for PCR reaction were an 
initial denaturing step of 5 min at 94 °C followed by 30 cycles of 94 °C for 1 min, 60 °C 
for 1 min and 72 °C for 1 min and then a final extension at 72 °C for 10 min. 
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Figure 2.2. Nucleotide and amino acid sequence of HA-AT1R. The introduction of 
HA epitope into AT1R gene is verified by sequencing. Red, EcoR1 restriction site; 
Green, sequence encoding HA epitope; blue, stop codons; magenta, Not1 restriction site, 
yellow, cysteine codons and residues. Disulfide bonded cysteines are framed.  
 
 
HA-AT1R Nucleotide Sequence 
 
GAATTCGCCACCATGTACCCATACGACGTCCCAGACTACGCGGCCCTTAACTCTTCTG 
CTGAAGATGGTATCAAAAGGATCCAAGATGACTGCCCGAAGGCTGGACGTCACAGTTA 
CATATTTGTCATGATTCCTACCCTCTACAGCATCATCTTTGTGGTGGGAATATTTGGA 
AACTCACTAGTGGTGATTGTCATTTACTTTTACATGAAGCTGAAGACTGTGGCCAGCG 
TCTTTCTTCTCAATCTCGCCTTGGCAGATTTATGCTTTTTGTTAACTTTGCCCCTGTG 
GGCAGTCTATACCGCCATGGAGTACCGCTGGCCCTTCGGTAACCACCTATGTAAGATC 
GCTTCGGCCAGCGTGAGCTTCAACCTCTACGCGTCTGTGTTCCTTCTCACTTGTCTCA 
GCATCGACCGCTACCTGGCCATCGTGCACCCAATGAAGTCTCGCCTACGTAGAACGAT 
GCTGGTGGCCAAAGTAACCTGCATCATCATCTGGCTGATGGCTGGCTTGGCTAGTTTG 
CCTGCAGTCATCCACCGAAATGTATACTTCATCGAGAACACCAATATCACAGTGTGCG 
CATTTCATTATGAGTCTCGAAATTCGACGCTCCCGATCGGGCTGGGCCTTACCAAGAA 
TATACTGGGCTTCTTGTTCCCTTTCCTTATCATTCTCACCAGCTATACCCTCATATGG 
AAAGCTCTAAAGAAAGCTTATGAAATTCAAAAGAACAAACCAAGAAACGATGACATCT 
TTCGAATAATTATGGCGATTGTGCTTTTCTTCTTCTTTTCTTGGGTACCCCACCAGAT 
ATTCACTTTCCTGGATGTGCTGATTCAGCTGGGCGTCATCCATGACTGTAAAATTTCT 
GACATCGTGGACACTGCCATGCCCATCACGATATGCATAGCGTATTTTAACAACTGTT 
TAAACCCTCTGTTTTACGGCTTTCTGGGGAAGAAATTCAAAAAGTACTTCCTCCAGCT 
CCTGAAATATATTCCCCCGAAGGCCAAGTCCCACTCGAGCCTGTCTACGAAAATGAGC 
ACGCTTTCTTACCGGCCTTCGGATAACATGAGCTCATCGGCCAAAAAGCCTGCGTCTT 
GTTTTGAGGTGGAGTAATAGGCGGCCGC 
 
HA-AT1R Amino Acid Sequence 
 
MYPYDVPDYAALNSSAEDGIKRIQDDCPKAGRHSYIFVMIPTLYSIIFVVGIFGNSLVV
IVIYFYMKLKTVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNHLCKIASASVS
FNLYASVFLLTCLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLMAGLASLPAVIHRN
VYFIENTNITVCAFHYESRNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYE
IQKNKPRNDDIFRIIMAIVLFFFFSWVPHQIFTFLDVLIQLGVIHDCKISDIVDTAMPI
TICIAYFNNCLNPLFYGFLGKKFKKYFLQLLKYIPPKAKSHSSLSTKMSTLSYRPSDNM
SSSAKKPASCFEVE 
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alanine. Please note that different cysteine codons were used to avoid potential 
consequence of high abundance of a single codon during translation.  The PCR products 
were fractionated on agarose gel, isolated by QIAquick Gel Extraction Kit (QIAGEN 
Sciences, Maryland), digested with appropriate restriction enzymes and purified with 
QIAquick PCR Purification Kit (QIAGEN Sciences, Maryland). The insert was 
subcloned into the synthetic gene which was digested with appropriate restriction 
enzymes at each step of mutagenesis. The schematic explanation of construction of 
CYS¯AT1R is given in Figure 2.3. The sequence of HA-CYS¯AT1R was confirmed by 
automated DNA sequencing.  
 
The single cysteine mutants of ECL2 were generated using PCR mutagenesis as 
described in Figure 2.4 A. Briefly, sense and antisense mutagenic primers, 
complementary to the CYS¯AT1R sequence and carrying the nucleotide changes (TGC) 
to produce the desired amino acid (cysteine), were designed to substitute each residue on 
ECL2 one at a time. The list of primers is given in Table II.I. The mutagenic primers 
along with EcoR1 and Not1 primers were simultaneously annealed to the denatured 
pMT3-HA-CYS¯AT1R template in the first PCR reaction. The full-length construct was 
obtained in the second PCR reaction by amplification with EcoR1 and Not1 primers. The 
PCR products were fractionated on agarose gel, isolated by QIAquick Gel Extraction Kit 
(QIAGEN Sciences, Maryland), digested with EcoR1 and Not1 and purified with 
QIAquick PCR Purification Kit (QIAGEN Sciences, Maryland). The insert was ligated 
into pMT3, digested with EcoR1 and Not1, and then transformed into competent DH5α 
cells (Fig. 2.4 B). The plasmids were isolated using QIAGEN Plasmid Maxi kit      
44
Figure 2.3. Schematic representation of construction of CYS¯AT1R. Single cysteine 
substitutions, C76A, C121A, C144A, C289A, C296A, C355A were created by 
mismatched primer method and combined as shown by PCR amplification. Primers are 
shown as arrows. (Courtesy, John Boros, Shin-ichiro Miura & S. Karnik)  
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Figure 2.4. Construction of ECL2 single cysteine mutants. A) Schematic explains the 
introduction of I172C substitution as an example. pMT3-HA¯CYS-AT1R was used as a 
template for PCR mutagenesis. The first PCR reaction involved either EcoR1 primer with 
I172C antisense primer or Not1 primer with I172C sense primer. The second PCR 
reaction annealed and amplified the purified fragments of the first PCR reaction in the 
presence of EcoR1 and Not1 primer. B) Left panel, PCR-1. Lane 1, EcoR1 & E173C 
antisense primers (product size: 571 kb); Lane 2, Not1 & E173C sense primers (product 
size: 613 kb); Lane 5, EcoR1 & N174C antisense primers (product size: 573 kb); Lane 6, 
Not1 & N174C sense primers (product size: 608 kb); Lane 9, EcoR1 & T175C antisense 
primers (product size: 577 kb); Lane 10, Not1 & T175C sense primers (product size: 605 
kb). Lanes 3, 7 & 11, negative control without template. Right panel, PCR-2 with EcoR1 
& Not1 primers. Lane 1, E173C PCR1 fragments of lanes 1 & 2 of left panel (product 
size: 1.2 kb); Lane 5, N174C PCR1 fragments of lanes 5 & 6 of left panel (product size: 
1.2 kb); Lane 9, T175C PCR1 fragments of lanes 9 & 10 of left panel (product size: 1.2 
kb). Lanes 2, 3, 6, 7, 10, 11, negative controls without either fragments.   
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B 
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Table II.I. The list of primers used for single cysteine substitutions.  
PRIMER SEQUENCE bp %GC TM 
I172C sense GTATACTTCTGCGAGAACACC 21 47.62 75.74
I172C antisense GGTGTTCTCGCAGAAGTATAC 21 47.62 75.74
E173C sense GTATACTTCATCTGCAACACCAATATC 27 37.04 80.92
E173C antisense GATATTGGTGTTGCAGATGAAGTATAC 27 37.04 80.92
N174C sense CTTCATCGAGTGCACCAATATCAC 24 45.84 84.55
N174C antisense GTGATATTGGTGCACTCGATGAAG 24 45.84 84.55
T175C sense CATCGAGAACTGCAATATCACAGTG 25 44.00 84.68
T175C antisense CACTGTGATATTGCAGTTCTCGATG 25 44.00 84.68
N176C sense CGAGAACACCTGCATCACAGTGTG 24 54.17 88.97
N176C antisense CACACTGTGATGCAGGTGTTCTCG 24 54.17 88.97
I177C sense GAACACCAATTGCACAGTGTGCGC 24 54.17 92.10
I177C antisense GCGCACACTGTGCAATTGGTGTTC 24 54.17 92.10
T178C sense CACCAATATCTGCGTGTGCGCATTTC 26 50.00 93.43
T178C antisense GAAATGCGCACACGCAGATATTGGTG 26 50.00 93.43
V179C sense CCAATATCACATGCTGCGCATTTC 24 45.84 89.13
V179C antisense GAAATGGCGAGCATGTGATATTGG 24 45.84 89.13
A181C sense CACAGTGTGCTGCTTTCATTATGAG 25 44.00 84.80
A181C antisense CTCATAATGAAAGCAGCACACTGTG 25 44.00 84.80
F182C sense CAGTGTGCGCATGCCATTATGAGTC 25 52.00 91.31
F182C antisense GACTCATAATGGCATGCGCACACTG 25 52.00 91.31
H183C sense GTGCGCATTTTGCTATGAGTCTCG 24 50.00 88.73
H183C antisense CGAGACTCATAGCAAAATGCGCAC 24 50.00 88.73
Y184C sense GCATTTCATTGCGAGTCTCGAAATTC 26 42.31 89.41
Y184C antisense GAATTTCGAGACTCGCAATGAAATGC 26 42.31 89.41
T185C sense GCATTTCATTATTGCTCTCGAAATTCG 27 37.04 88.17
T185C antisense CGAATTTCGAGAGCAATAATGAAATGC 27 37.04 88.17
S186C sense CATTATGAGTGCCGAAATTCGACG 24 45.84 88.23
S186C antisense CGTCGAATTTCGGCACTCATAATG 24 45.84 88.23
R187C sense CATTATGAGTCTTGCAATTCGACG 24 41.67 84.56
R187C antisense CGTCGAATTGCAAGACTCATAATG 24 41.67 84.56
N188C sense GAGTCTCGATGCTCGACGCTCCCG 24 66.67 95.83
N188C antisense CGGGAGCGTCGAGCATCGAGACTC 24 66.67 95.83
S189C sense GTCTCGAAATTGCACGCTCCCGATC 25 56.01 94.06
S189C antisense GATCGGGAGCGTGCAATTTCGAGAC 25 56.01 94.06
T190C sense CTCGAAATTCGTGCCTCCCGATCG 24 58.34 94.83
T190C antisense CGATCGGGAGGCACGAATTTCGAG 24 58.34 94.83
L191C sense GAAATTCGACGTGCCCGATCGGGC 24 62.5 97.90
L191C antisense GCCCGATCGGGCACGTCGAATTTC 24 62.5 97.90
P192C sense GAAATTCGACGCTCTGCATCGGGCTG 26 57.70 97.10
P192C antisense CAGCCCGATGCAGAGCGTCGAATTTC 26 57.70 97.10
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(QIAGEN Sciences, Maryland). The agarose gel fractionation of CYS¯AT1R and 20 
single cysteine mutants is shown in Figure 2.5. All receptor mutants were confirmed by 
automated DNA sequencing.  
 
2.2 Cell Culture and Transfection 
For expression in mammalian cells, we used COS1 cell line (American Type 
Culture Collection, Rockville, MD) which is a green monkey kidney fibroblast cell line. 
This cell line has been transformed with the large T antigen of SV40 which also 
immortalizes the cell line. High levels of expression can be achieved transiently by 
transfecting COS1 cells with plasmids that carry the SV40 origin of replication. COS1 
cells were grown and maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with penicillin/streptomycin and 10% fetal bovine serum. Cell cultures 
were incubated at 37 °C in 5% CO2. 
 
COS-1 cells were grown in 100-mm culture dishes to approximately 60-70% 
confluence and transiently transfected by FuGENE 6 Transfection Reagent (Roche 
Applied Science, IN) according to manufacturer’s instructions. Briefly, 18 µl of FuGENE 
6 reagent was added into 600 µl of OPTI-MEM reduced serum media. 6 µg plasmid 
DNA was then added and incubated for 15 min at room temperature. The mixture was 
then added into the culture medium. The transfection efficiency was 40-50 % as 
determined by transfection of cells with a plasmid encoding both AT1R and green 
fluorescent protein (GFP) (Fig. 2.6). 
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Figure 2.5. The agarose gel fractionation of HA-CYS¯AT1R and 20 single cysteine 
mutants. 2 µg plasmid DNA is dissolved in H2O in a total volume of 20 µl. 4 µl of 6X 
loading dye (Promega, WI) is added. M, 2 µl of 1 Kb Plus DNA ladder (Invitrogen) 
mixed with 14 µl of TE buffer and 4 µl of 6X loading dye. Samples were run on 1 % 
agarose gel at 90 Volts. 
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Figure 2.6. Transfection efficiency in COS1 cells. A) Phase picture of COS1 cells 
(Magnification X10). B) COS1 cells transfected with pEGFP-AT1R (Magnification 
X10). The transfection efficiency was estimated by a rough count of [number of GFP 
cells/number of DAPI stained cellsx100%]. 
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2.3 Western Blotting 
After 48 hours incubation, transfected cells were placed on ice and washed twice 
with ice-cold phosphate buffered saline (PBS). Cells were scraped and transferred into 
centrifuge tubes and spun at 3900 rpm for 5 min at 4°C. Cells were lysed in Mammalian 
Protein Extraction Reagent (MPER, 25mM bicine, CHAPS and N-tetradecyl-N, N-
dimethyl-3-ammonia-1 propanesulfonate) (Pierce) containing protease (Sigma) and 
phosphatase inhibitors (Thermo Scientific) with continuous rotation at 4°C for 25 min. 
The lysate was centrifuged at 13200 rpm for 10 min at 4°C and the supernatant was 
analyzed for protein concentration by Bradford method (Bradford, 1976) using bovine 
serum albumin (BSA) as a concentration standard. 50 μg of protein from each sample 
was incubated with 4X NuPAGE LDS sample buffer (Invitrogen) containing 10% 2-
mercaptoethanol at room temperature for 5 min and resolved on 10% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Invitrogen) and electroblotted 
onto nitrocellulose membrane (0.45 µm) (Bio-Rad). The membrane was blocked in 
blocking buffer (PBS with 0.5 % Tween-20 and 5% nonfat dried milk) for 1 hour at room 
temperature. The membrane was then incubated with mouse anti-HA monoclonal 
antibody (Roche) (1:1000) in blocking buffer at 4°C for overnight. The membrane was 
washed three times for 10 min each with PBST (PBS containing 0.5 % Tween-20) and 
incubated with HRP-conjugated anti-mouse IgG (GE Healthcare) (1:5000) in blocking 
buffer for 1 hour at room temperature. The membrane was washed and the receptor 
expression was detected using ECL Plus western blotting detection system (Amersham).  
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2.4 Immunocytochemistry 
24 hours post-transfection, cells were plated onto poly-L-lysine coated coverslips 
placed in 6-well culture dishes. Cells were cultured for 24 hours in DMEM supplemented 
with 10% fetal bovine serum and switched to serum-free DMEM 18 h before treatment. 
Cells were fixed with 4% paraformaldehyde in PBS for 30 min and washed three times 
with PBS for 10 min each. Cells were then permeabilized with 0.3% Triton X-100 in PBS 
for 20 min on ice and blocked with 5% nonfat dry milk in PBS for 1 hour at room 
temperature. Cells were incubated overnight with mouse anti-HA monoclonal antibody 
(1:1000) in blocking buffer at 4°C, washed and incubated with AlexaFlour 568 anti-
mouse antibody (1:2000) for 1 hour at room temperature in the dark. Cells were then 
washed and mounted on coverslips on glass slides for confocal microscopy analysis.  
 
2.5 Saturation Binding Assays 
72 hours post-transfection, cells were placed on ice and washed twice with ice 
cold PBS. Cells were gently scraped and transferred into centrifuge tubes and spun at 
1000 rpm for 5 min at 4 °C. Cells were gently resuspended in binding buffer (140 mM 
NaCl, 5.4 mM KCL, 1mM EDTA, 0.006% BSA, 25 mM HEPES, pH 7.4). Protein 
concentration was determined by Bradford method (Bradford, 1976) using BSA as a 
concentration standard. Binding assays were performed under equilibrium conditions, 
with [125I]-[Sar1,Ile8] Ang II (Dr. Robert Speth, University of Mississippi) concentrations 
ranging between 0.125-12 nM (specific activity: 2176 Ci/mmol) for 1 hour at room 
temperature as previously described (Noda et al, 1996, Miura et al, 2002 & Miura et al, 
2003). Nonspecific binding was measured in the presence of 10-5M [127I]-[Sar1Ile8] Ang 
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II (Bachem). 25 μl of binding buffer or [127I]-[Sar1Ile8] Ang II was mixed with 50 μl of 
increasing concentrations of [125I]-[Sar1,Ile8] and 50 μl of cell suspension in total volume 
of 125 μl. Each concentration was repeated in duplicates in 96-well plates. The cells were 
harvested with Combi cell harvester (Skatron Instruments, Norway) by filtering the 
binding mixture through Whatman GF/C glass fiber filters (102×256 mm), which were 
extensively washed with washing buffer (20 mM sodium phosphate, 100 mM NaCl, 10 
mM MgCl2, 1 mM EGTA, pH 7.2) . The bound ligand fraction was determined using 
10/600 Apex gamma counter (Titertek Instruments) as the counts per minute (cpm) 
remaining on the membrane. The binding kinetics was analyzed by nonlinear curve 
fitting program LigandR which yields mean±S.D. for Kd and Bmax values. 
 
2.6 Analysis of ERK Phosphorylation 
48 hours post-transfection, cells were serum starved for 18 h and treated with 1 
μM Ang II (Bachem) for 10 min at room temperature. Cells were washed twice with ice-
cold PBS. Cells were lysed and immunoblotted as described above and the membrane 
was blocked in blocking buffer (PBS with 0.5 % Tween-20 and 5% BSA) for 1 hour at 
room temperature. The membrane was incubated overnight with phospho-ERK 
42/44MAPK polyclonal antibody (Cell Signaling) (1:1000) in blocking buffer. The 
membrane was then washed and incubated with HRP-conjugated anti-rabbit IgG (1:5000, 
GE Healthcare) in blocking buffer for 1 hour at room temperature. Immunoreactivity was 
detected using ECL Plus western blotting detection system. The membranes were 
stripped and similarly analyzed for total ERK 42/44MAPK (Cell Signaling) reactivity. 
54
Results were used to correct pERK 42/44MAPK measurements for slight differences in 
sample protein content. 
 
2.7 Intracellular Calcium Measurement 
Changes in cytoplasmic Ca2+ were measured using fluorescent calcium indicator 
Fura-2 (excitation maximum 340 and 380 nm; emission maximum 510 nm) (Invitrogen) 
(29). The principle of Ca2+ measurement assay by Fura-2 is explained in Figure 2.7. Cells 
were grown on coverslips in 6-well culture dishes. 48 hours post transfection, cells were 
loaded with 1 μm Fura-2 acetoxymethyl ester 2 in BSS-Ca2+ buffer (140 mM NaCl, 5 
mM KCl, 1.2 mM MgCl2, 5.5 mM Glucose, 10 mM Hepes, 0.1% BSA and 2 mM CaCl2, 
pH 7.4). After 30 min incubation at 37 °C cells were washed with BSS-Ca2+ to remove 
the extracellular dye. Calcium measurements were done in single cells using an inverted 
microscope (Zeiss Axiovert 135) connected to a CCD camera (Photon Technology 
International). The data were collected at 1.5-s intervals and analyzed using Image Master 
software (Photon Technology International). The release of intracellular Ca2+ in 
individual cells was measured after exposure to 1 µM Ang II in BSS-Ca2+ by rapid 
solution exchange. Results were presented as average changes in the ratio of Fura-2 
fluorescence upon excitation at 340 nm and 380 nm and plotted using SigmaPlot.  
 
2.8 MTSEA-biotin Labeling 
MTSEA-biotin (N-biotinylaminoethylmethanethiosulfonate, Toronto Research 
Chemicals) in powder was stored as desiccated, dissolved in DMSO and aliquots of 0.1M 
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Figure 2.7. Intracellular Calcium measurement by Fura2. A) Fura-2 is a membrane 
impermeable UV-excitable fluorescent calcium indicator. Fura2-acetoxymethyl (Fura-
2AM) is a membrane-permeable derivative of the Fura2. Once inside the cells, the 
acetoxymethyl groups are removed by cellular esterases. Removal of the acetoxymethyl 
esters traps Fura2 inside the cells. B) Fura2 is a ratiometric dye which is excited at 
340 nm and 380 nm. The ratio of the emissions at 510 nm is directly correlated to the 
amount of intracellular calcium. 
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stock aqueous solutions were thawed just prior to use and kept on ice. Experiments were 
repeated at least three times as described below. 48 h post-transfection, cells were washed 
twice with PBS, harvested using non-enzymatic cell dissociation solution (Sigma) and 
suspended in PBS. 500 μl aliquots of cells were incubated with 10 mM MTSEA-biotin at 
25 °C for 30 min. The incubation time and MTSEA-biotin concentration were 
standardized to obtain maximum signal strength (Fig. 2.8). The reaction was stopped by 
diluting with cold PBS. Cells were spun at 3900 rpm for 5 min at 4 °C and resuspended 
in NP40 lysis buffer [1% NP40, 20 mM Tris (pH 7.4), 137 mM NaCl, 20% glycerol, and 
protease and phosphatase inhibitors]. Protein concentration was determined by Bradford 
method (Bradford, 1976) using BSA as a concentration standard. 750 μg of protein was 
incubated overnight with 4 μl of mouse anti-HA monoclonal antibody in lysis buffer. The 
receptors were immunoprecipitated with Protein-G agarose beads (Millipore) by 
continuous rotation for 2 hours at 4 °C. Beads were then washed four times with cold 
PBS and proteins were extracted by heating at 70°C in NuPAGE LDS sample buffer for 
10 min. Samples were immunoblotted as described above and probed with Streptavidin-
HRP (Amersham) according to manufacturer’s instructions. Biotinylation level of 
receptors was determined using KODAK 1D 3.6. To control for the differences of 
receptors’ expression levels, the same blot was reprobed with anti-HA antibody as 
described above. MTSEA-biotin accessibility of each receptor was obtained by 
normalizing the biotinylation level of each receptor to its expression level. The same 
procedure was repeated following either 1 µM Ang II (Bachem) or 1 µM losartan 
(DuPont Merck Co, Wilmington, DE) treatment for 10 min at room temperature (Fig 
2.9). 
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Figure 2.8. Assay standardization. A) Immunoprecipitation control experiment of HA-
CYS¯AT1R (lane 1) and HA-AT1R (lane 3) with anti-HA antibody. Negative controls 
lack anti-HA antibody (lanes 2 and 4). Untransfected cells are also shown as negative 
controls. The fully glycosylated monomeric receptor band is shown by arrow. B) 
Standardization of MTSEA-biotin concentration was performed with 2 mM, 5 mM and 
10 mM MTSEA-biotin concentrations. C) Standardization of incubation time was 
performed with 0-10 min time points using 10 mM MTSEA-biotin. 
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Figure 2.9. Experimental strategy for MTSEA-biotin accessibility measurement.  
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2.9 Molecular Dynamics Simulations 
Molecular Dynamics (MD) simulations were performed using the MD software 
package NAMD (Phillips et al, 2005) and the CHARMM 22.  The modeled structure of 
AT1R (PDB ID: 2AC6) and AT1R with Ang II (PDB ID: 2AH3) (Gogonea and Karnik, 
2006) was downloaded from the Protein Data Bank, and explicit hydrogen were added 
using the package VEGA ZZ 2.0.7 (Pedretti et al, 2004). This structure was subjected to 
1000 steps of energy minimization. The energy-minimized system was heated from 0°C 
to 310°C in 31°C intervals over the course of 20,000 steps. Simulations were carried out 
for 14 ns. The root-mean-square deviation of the backbone of AT1R with Ang II was 
stabilized after 7 ns. MD simulations were carried out using the molecular modeling 
software VEGA ZZ 2.0.7. We simulated ECL2 residues (Ile165- Pro192) with selected loop 
constraints and other receptor regions were not simulated. The ECL2 simulations were 
carried out by imposing Cys101-Cys180 disulphide bond as a constraint in different states. The 
disulphide bond constraint was relaxed for 1 ns at the end of 14 ns simulation. We used PyMOL 
(DeLano Scientific LLC) to visualize the output. A schematic explanation for steps of 
MD simulation is given in Figure 2.10. 
 
2.10 Losartan Docking 
Blind docking was carried out using AutoDock4 Vina (Trott and Olson, 2009). 
The starting conformation of losartan was an energy minimized form. The receptor was 
held rigid during the docking process while the ligand was allowed to be flexible to save 
computational time. The grid box size was 38.0A˚ -20.8A˚-26.4A˚ in the x, y and z 
dimensions, with the center of the grid corresponding to the central axis of the pore at 
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Lys199 and His256 at the base of the selectivity filter. Exhaustiveness was set as default. 
We used PyMOL to visualize the output.  
 
2.11 Statistical Analysis 
The results are expressed as the means ± Standard error of mean (SEM) and analyzed by 
unpaired t test for statistical significance to compare variables between mutants and wild type 
using Graphpad PrismR. Significance is set at p < 0.05. 
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Figure 2.10. Schematic explanation of MD simulation procedure.  
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CHAPTER III 
HA-CYS¯AT1R 
 
3.1 Introduction 
The structural analysis of transmembrane proteins such as AT1R through direct 
techniques, including x-ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy has been challenging. AT1R is expressed at very low levels (40-80 
fmoles/mg) in native tissues. In addition, the structural flexibility of AT1R causes 
thermodynamic and proteolytic instability during detergent-solubilization and 
purification. Many of these experimental constrains have been overcome by higher level 
expression (>100-fold compared to native cells) of receptor genes in recombinant 
systems. Increasing the level of expression of a GPCR often requires alteration of some 
structural features, such as attachment of a signal sequence, introduction of stabilizing 
mutations, or deletion of some segments of the receptor. Recombinantly expressed β2 
adrenergic, β1 adrenergic and the adenosine A1 receptors have been crystallized. Thus, 
protein engineering and recombinant expression of GPCRs has advanced the 
understanding of structure-function relationships of GPCRs.  
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Even when the high-resolution crystal structure is obtained, it represents a rigid, 
single conformation of a GPCR. We need other approaches to address questions 
concerning the dynamics and conformational changes associated with different states of 
activation, which allow the receptor to interact with a variety of diffusible ligands and 
generate diverse intracellular responses. Therefore we require additional indirect 
techniques to elucidate the dynamic properties of GPCRs such as AT1R. We planned to 
use a cysteine accessibility mapping approach to determine the dynamic changes in 
AT1R in different states including unbound, agonist-bound and antagonist-bound states. 
As described in Section 1.4, our accessibility mapping strategy requires introduction of 
cysteine residues into the region of interest one-at-a-time and measurement of the level of 
reactivity of engineered cysteines with thiol-specific alkylating reagents, which estimate 
the water accessibility of each residue.  
 
To effectively use this technique for AT1R, it would be ideal to construct a 
receptor which lacks all non-disulfide bonded cysteine residues. AT1R has ten native 
cysteines, four of which are disulfide bonded and six of which are not disulfide bonded 
(Fig. 3.1). Two disulfide bonds in the AT1R are critical for maintaining the 7 TM 
structure and the conformational changes associated with receptor activation/inhibition 
(Ohyama et al, 1995, Feng et al, 2000). Disulfide bonded cysteines also do not react with 
thiol-specific alkylating reagents. Some of the free cysteines may be buried during 
folding of the receptor to the three dimensional structure and may not be accessible to the 
thiol-specific alkylating reagents. However, one can not be sure if the buried cystines are 
exposed during receptor activation or inhibition. The cysteines that are partially      
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Figure 3.1. The secondary structure model of HA-CYS¯AT1R. Native non-essential 
free cysteine residues, Cys76, Cys121, Cys144, Cys289, Cys296 and Cys355, substituted with 
alanine are shown in green circles. Native cysteines involved in formation of essential 
disulfide bonds, Cys18-Cys274 and Cys101-Cys180, are shown in gold circles. 
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accessible might interfere with the accessibility measurements of engineered cysteines. 
Therefore we created a receptor surrogate of HA-AT1R named as HA-CYS¯AT1R that 
lacks all non disulfide-bonded cysteines. It is very important to rigorously characterize 
the modified protein for functionality to be able to use it for mapping the conformation 
associated with different states of the receptor. In this chapter we describe the 
construction and characterization of HA-CYS¯AT1R. We show that pharmacological and 
signal transduction properties of HA-CYS¯AT1R are similar to those of HA-AT1R.  
 
3.2 HA-CYS¯AT1R Nucleotide Sequence Confirmation 
The mutagenesis steps used in the construction of HA-CYS¯AT1R are 
schematized in detail in Figure 2.1. In the HA-CYS¯AT1R, native cysteines involved in 
the formation of disulfide bonds, Cys18-Cys274 and Cys101-Cys180, which are essential for 
receptor stability (Ohyama et al, 1995 & Feng et al, 2000) were not mutated (Fig. 3.1). 
The codons for these cysteine residues were unaltered (Table III.I). Codons for other 
native non-essential free cysteine residues (Cys76, Cys121, Cys144, Cys289, Cys296 and 
Cys355) were substituted with alanine codons. The substituted alanine codons in the HA-
CYS¯AT1R that were confirmed by DNA sequencing are listed in Table III.I. A 
comparison of nucleotide sequences of HA-AT1R and HA-CYS¯AT1R is shown in 
Figure 3.2 for three representative alanine substituted cysteine codons; Cys76, Cys121 and 
Cys149. The HA-CYS¯AT1R will serve as the background to introduce reporter cysteine 
residues in the ECL2. 
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Table III.I Cysteine substitutions in HA-CYS¯AT1R. HA-AT1R was subjected to 
site-directed mutagenesis as described in Section 2.1, creating HA-CYS¯AT1R in which 
6 of the 10 cysteine residues of HA-AT1R was substituted with alanine. DNA sequence 
analysis confirmed C76A, C121A, C144A, C289A, C296A, C355A substitutions in 
HA¯CYS-AT1R as shown. The codons for Cys18, Cys101, Cys180 and Cys274 which are 
involved in disulfide bond formation were not modified as indicated in bold. The DNA 
sequencing chromatogram for corresponding residues of HA-CYS¯AT1R is also shown. 
Green, A; Red, T; Blue, T; Black, G. 
HA-AT1R HA¯CYS-AT1R  Codon change Chromatogram
Cys18 Cys18 TGC → TGC  
 
Cys76 Ala76 TGC → GCC  
 
Cys101 Cys101 TGT → TGT  
 
Cys121 Ala121 TGT → GCT  
 
Cys149 Ala149 TGC → GCC  
 
Cys180 Cys180 TGC → TGC  
 
Cys274 Cys274 TGT → TGT  
 
Cys289 Ala289 TGC → GCC  
 
Cys296 Ala296 TGT → GCT  
 
Cys355 Ala355 TGT → GCA  
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Figure 3.2. Comparison of chromatograms of HA-AT1R and HA¯CYS-AT1R. The 
sequences of Cys76, Cys121 and Cys149 positions of HA-AT1R and the corresponding 
alanine substitutions in HA¯CYS-AT1R are shown as an example. Green, A; Red, T; 
Blue, T; Black, G. 
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3.3 Characterization of HA-CYS¯AT1R 
The expression of HA-AT1R and HA-CYS¯AT1R, compared by immunoblotting, 
showed similar levels in transiently transfected COS1 cells. Both receptors appear to be 
fully glycosylated (41.9 kDa). When analyzed by SDS-PAGE, unglycosylated (~37 kDa) 
and partially glycosylated (~40 kDa) monomeric forms of the receptors as well as small 
amounts of higher molecular weight oligomers (50-80 kDa) were present (Fig. 3.3 A) in 
both. Other properties in terms of cell surface expression, cellular localization, binding 
affinity for Ang II and agonist activated signaling were compared. Immunocytochemical 
anlaysis indicated that both HA-AT1R and HA-CYS¯AT1R were expressed on the 
plasma membrane at similar levels (Fig. 3.3 B). The Kd values of HA-AT1R and HA-
CYS¯AT1R for the peptide antagonist 125I-[Sar1, Ile8]Ang II, obtained by saturation 
binding analysis performed on intact cells, were 3.5 nM and 4.4 nM, respectively (Fig 3.4 
A). The cell surface Bmax values measured from scatchered plots were 3.5 pmol/mg and 
5.8 pmol/mg for HA-AT1R and HA-CYS¯AT1R respectively (Fig. 3.4 B).  
 
          To analyze the Ang II-induced signal transduction capacity of HA-CYS¯AT1R, we 
measured ERK1/2 activation and intracellular Ca2+ release upon 1 µM Ang II treatment 
(Fig. 3.5 A).  The level of ERK1/2 activation of HA-CYS¯AT1R was comparable to HA-
AT1R (Fig. 3.5 B). The Ang II-induced ERK1/2 activation was inhibited by the AT1R-
selective non-peptide antagonist, losartan (Fig. 3.5 B). Ang II-induced mobilization of 
intracellular calcium, which is a measure of G protein activation, was similar in HA-
CYS¯AT1R and HA-AT1R (Fig. 3.5 C). These results suggested that cell surface    
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Figure 3.3. Expression analysis of HA-AT1R and HA-CYS¯AT1R. A) Western blot 
analysis of HA-AT1R (lane 4) and HA-CYS¯AT1R (lane 5) expression in COS1 cells. 
Cells which are mock transfected (MT) (lane 1), transfected with pMT3 (lane 2) and 
CYS¯AT1R without HA tag (lane 3) are shown as negative controls. The 64 kDa band 
corresponds to a nonspecific, cross reacting protein. 3 differentially glycosylated 
monomeric bands of the receptor are identified as fully-, partial- and single-glycosylated 
bands. Higher molecular weight oligomeric forms of the receptor can be seen between 
51-80 kDa. B) The localization of HA-AT1R (panel 2) and HA-CYS¯AT1R (panel 3) on 
the plasma membrane of COS1 cells. Untransfected cells are shown as negative control 
(panel 1). Cells were labeled with DAPI (blue) for nucleus and with mouse HA 
monoclonal primary antibody and Alexa flour 568 (red) anti-mouse secondary antibody 
for HA-tagged receptors. Plasma membrane is indicated by yellow arrow. 
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Figure 3.4. Binding analysis of HA-AT1R and HA-CYS¯AT1R. A) Saturation curves 
of HA-AT1R and HA-CYS¯AT1R determined using [125I]-[Sar1, Ile8] Ang II. Inset 
shows the corresponding Scatchard plot. B) Cell surface density of HA-AT1R and HA-
CYS¯AT1R expressed as mean Bmax values derived from Scatchard plots. Error bars 
indicate the S.E.M., p=0.082 (n=3). 
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Figure 3.5. Activity analysis of HA-AT1R and HA-CYS¯AT1R. A) The signal 
transduction pathway of AT1R activated by Ang II binding. The intracellular Ca2+ 
release and MAPK activation were analyzed as read-out of Ang II induced activity. B) 
ERK1/2 phosphorylation (p-ERK) upon treatment with 1 μM Ang II on untransfected 
cells (lanes 1-2), HA-AT1R (lanes 3-4) and HA-CYS¯AT1R (lanes 7-8) transfected cells. 
ERK1/2 phosphorylation is inhibited by losartan treatment prior to Ang II treatment (lane 
5 & 9) and together with Ang II treatment (lane 6 & 10). Total ERK (t-ERK) levels are 
shown as loading control. The plot corresponds to the p-ERK/t-ERK ratio of lanes 
3,4,6,7,8,10. C) Measurement of intracellular Ca2+ mobilization upon 1 μM Ang II 
treatment in HA-AT1R and HA-CYS¯AT1R transfected COS1 cells. The time point of 
Ang II treatment is indicated by the arrow.  
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expression, Ang II binding affinity, activation and inhibition properties of HA-
CYS¯AT1R are comparable to those of wild type HA-AT1R.    
 
3.4 Reaction of HA-AT1R and HA-CYS¯AT1R with Cysteine Reactive MTSEA-
biotin 
We anticipated that the HA-CYS¯AT1R would not react with thiol-specific 
modifying reagent, MTSEA-biotin (N-biotinylaminoethylmethanethiosulfonate). 
MTSEA-biotin consists of a biotin moiety attached to the highly reactive 
methanethiosulfanate. The MTSEA-biotin (Fig. 3.6 A) does not react with disulfide 
bonded or buried cysteine residues, but rapidly reacts with water-exposed reactive 
cysteines (Akabas et al, 1992).  
 Protein    SH + CH3   S   S   biotin            Protein   S   S   biotin + CH3   S    H 
O 
O O
O
 
The resulting site-specific covalent attachment of biotin (red) to engineered 
cysteine was detected by streptavidin-HRP. Figure 2.9 explains the MTSEA-biotin 
labeling strategy. The receptor topology was preserved during MTSEA-biotin reaction as 
closely as possible to the native state in the plasma membrane by using adherent cells 
rather than fractionated membranes.  
 
The anticipated reaction of HA-AT1R and HA-CYS¯AT1R with MTSEA-biotin 
is depicted in Figure 3.6 A. Theoretically; HA-AT1R carrying 6 free cysteines is 
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expected to be six times more reactive to MTSEA-biotin compared to HA-CYS¯AT1R, 
which lacks all the free cysteines. We compared the reactivity of HA-AT1R and HA-
CYS¯AT1R with MTSEA-biotin (Fig. 3.6 B). Following MTSEA-biotin treatment, 
detergent solubilized HA-tagged receptors were immunoprecipitated using anti-HA 
antibody and probed with streptavidin-HRP. Band intensities observed by HA blot were 
similar, which controls for expression levels of two receptors. Fully glycosylated 
monomeric receptor band was monitored for the quantification (Fig. 3.6 C). The level of 
biotinylation was estimated by normalizing the streptavidin-HRP signal to the HA signal 
for each sample. MTSEA-biotin modification of HA-AT1R which has six native free 
cysteines is ≈ 2-fold more than HA-CYS¯AT1R which lacks those cysteines (Fig. 3.6 D). 
This result is consistent with the previous study by Miura & Karnik (2002), which 
demonstrated that among the 6 native free cysteines in wild type AT1R, only Cys76 in 
TMII of AT1R is fully reactive to MTSEA (Fig. 3.7). The native Cys289 and Cys296 were 
partially reactive to MTSEA. The authors measured the MTSEA sensitivity of native 
cysteine residues of the AT1R and individual Cys→Ala mutants. This data explains our 
observation of 2-fold more reactivity of HA-AT1R compared to HA-CYS¯AT1R.  
 
The results discussed in this chapter suggest that HA-CYS¯AT1R is functionally 
similar to HA-AT1R. It appears that the disulfide bonds are formed appropriately and 
maintain the stability of the HA-CYS¯AT1R as anticipated. The four disulfide bonded 
cysteine residues in AT1R are sufficient for proper folding and maintenance of the 
tertiary structure of the receptor polypeptide. It is quite impressive to observe that 
replacing six free cysteines did not alter expression and affinity of the receptor for both 
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Figure 3.6. MTSEA-biotin accessibity of HA-AT1R and HA-CYS¯AT1R. A) The 
anticipated reaction of HA-AT1R which has 6 free cysteines with 6 MTSEA-biotin. B) 
HA and Streptavidin-HRP blots comparing levels of expression and MTSEA-biotin 
labeling, respectively. The band representing the fully-glycosylated, mature form of the 
receptor that has been used for quantification of MTSEA-biotin relative accessibility is 
shown in red box. C) The cropped image of panel A only indicates the receptor band that 
has been used for quantification of MTSEA-biotin relative accessibility. D) The 
corresponding plot shows the MTSEA-biotin relative accessibility which is the ratio of 
Streptavidin-HRP signal intensity to HA signal intensity for particular sample. The red 
line indicates the level of biotinylation of HA-CYS¯AT1R without any free cysteine 
which is determined as the cut-off below which the reactivity is considered inaccessible. 
The observed stoichiometry of the reaction is shown. 
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Figure 3.7. Inhibition of ligand binding following reaction of MTSEA with AT1R 
and CYS¯AT1R. A) Time course inhibition of specific binding of 125I-[Sar1, Ile8] Ang II 
to the AT1R and mutant receptors, CYS¯AT1R, C76A, C289A and C296A after 
treatment with 2.5 mM MTSEA. B) Dose response inhibition of specific binding to the 
AT1R and mutant receptors, CYS¯AT1R, C76A and C289A after treatment with 2.5 mM 
MTSEA. Details are given in references 5 and 7. In the wild type receptor, MTSEA 
inhibited [Sar1,Ile8]Ang II binding whereas binding in the CYS¯AT1R and C76A mutant 
was resistant to MTSEA reaction. Therefore, the inhibition of [Sar1, Ile8]Ang II binding is 
due to reaction of MTS reagents with Cys76 in the TMII and the remaining free cysteine 
residues are not accessible (from Miura & Karnik, 2002).   
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agonist and antagonist.  The Cys355 in AT1R is analogous to the cysteine residue that is 
palmitoylated in rhodopsin and adrenergic receptors. The palmitoylated cysteine may 
stabilize the C-terminal tail of the receptor by providing a pseudo cytoplasmic loop 
(Sachs et al, 2000). However, the substitution of Cys355 with alanine did not affect the 
stability and function of the AT1R in our study. In addition HA-CYS¯AT1R is less 
sensitive to MTSEA-biotin compared to HA-AT1R. Therefore, we used the HA-
CYS¯AT1R as a template to create 20 single cysteine substituted ECL2 mutants used in 
our accessibility analysis. 
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CHAPTER IV 
CYSTEINE SCANNING MUTAGENESIS 
 
4.1 Introduction 
Chemical reactions that are rather specific for functional groups of each type of 
amino acid side chain have historically played a significant role in the development of 
foundational concepts of protein structure and function. Chemical modifications are 
possible for several residues carrying reactive groups on their side chains, including 
histidine, lysine, arginine, methionine, tryptophane, tyrosine and cysteine. Wider use of 
chemical modification is hampered because modification reactions use harsh conditions 
which may cause structural or conformational changes in the protein, affecting the 
biological function. The thiol group of cysteine residues is one of the most versatile 
functional groups, amenable to probing in terms of surface location or burial, location in 
static or dynamic regions of proteins. The cysteine thiol group is the most reactive among 
the functional groups of amino acids. Many reagents are available that specifically react 
with thiol groups. Thiol groups can be modified through metal binding, acylation, 
alkylation, cyanylation and oxidation under conditions that preserve the relevant 
biological functions of proteins (Chalker et al, 2009).  
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The advent of site-directed mutagenesis expanded the use of cysteine thiols as reporter 
groups in defining details of protein structure, function and dynamics that are not easily 
approachable by time-consuming methodologies including crystallography and NMR, 
which also require very expensive instrumentation. In many instances the reporter 
cysteine mapping is the only practical approach to study the protein in its native 
microenvironment. Cysteine substitutions can be directed to any region of a protein. The 
overwhelming experience is that the substituted cysteines are well tolerated in most 
biological systems. In the study of TM receptors, cysteine scanning mutagenesis is the 
method of choice because very few cysteine substitution mutants fail to yield functional 
receptors on the cell surface. Thus, cysteine substitutions are very well tolerated (Kaback 
et al, 1997).  
 
In this chapter, we describe an extensive characterization of single cysteine 
mutants in ECL2, a 20 residue long segment of the extracellular domain of AT1R with 
poorly defined functions. It is necessary to ascertain that no gross conformational change 
occurred in the AT1R upon each modification. Only cysteine substitution mutants with 
near wild-type function can be used for further modification because we assume that the 
substituted cystiene side chain has wild-type-like orientation and rotational freedom.  
 
4.2 Expression Analysis of ECL2 Single Cysteine Mutants  
The mutagenesis strategy used in the construction of ECL2 mutants is 
schematized in detail in Figure 2.4. DNA sequencing confirmed that each native residue 
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in ECL2 was substituted with a cysteine, one at a time. The substituted cysteine codons in 
the ECL2 mutants are listed in Table IV.I. 
 
The expression of each single cysteine substitution mutant upon transient 
transfection of COS1 cells was determined by western blotting. Western blot analysis 
showed that most of the mutant receptors were expressed at a similar level to that of HA-
CYS¯AT1R. Transient transfection of 18 single cysteine mutant plasmids yielded ≈ 42 
kDa fully glycosylated mature form of the functional receptor protein in COS1 cells (Fig. 
4.1). Variable expression seen due to variability in transient transfection was not 
statistically significant. Thus introduction of cysteine side chains at 18 different positions 
of ECL2 in the AT1R did not significantly interfere with the overall folding and transport 
to cell surface.  
 
The expression level of mutant I177C was reduced and the V179C mutant 
receptor protein appeared to be degraded. To understand the reasons for instability of 
these two mutant receptors in COS1 cells, we carried out additional site directed 
mutagenesis. Serine substitution for Ile177 significantly reduced the expression whereas 
substitution of alanine was normal. This suggested that a hydrophobic residue is essential 
at position 177 for normal expression of the receptor (Fig. 4.2). Substitution of both 
serine and alanine for Val179 produced stable receptor protein, suggesting that the 
cysteine side chain introduced at position 179 causes instability. The reasons for 
instability of these mutant receptors are unclear. However, since Ile177 and Val179 are n-3 
and n-1 positioned residues from conserved Cys180, the side chains of these residues may  
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Table IV.I. Cysteine scanning mutagenesis of ECL2. HA-CYS¯AT1R was subjected 
to oligonucleotide mediated site-directed mutagenesis, creating a series of 20 mutants in 
which each of the 20 residues within ECL2 was individually changed to cysteine. The 
native disulfide bonded cysteine is indicated in bold.  
 
Residue no Amino acid change Codon change 
172 Ile  → Cys ATC → TGC 
173 Glu  → Cys GAG → TGC 
174 Asn  → Cys AAC → TGC 
175 Thr  → Cys ACC → TGC 
176 Asn  → Cys AAT → TGC 
177 Ile  → Cys ATC → TGC 
178 Thr  → Cys ACA → TGC 
179 Val  → Cys GTG → TGC 
180 Cys  → Cys TGC → TGC 
181 Ala  → Cys GCA → TGC 
182 Phe  → Cys TTT → TGC 
183 His  → Cys CAT → TGC 
184 Tyr  → Cys TAT → TGC 
185 Glu  → Cys GAG → TGC 
186 Ser  → Cys TCT → TGC 
187 Arg  → Cys CGA → TGC 
188 Asn  → Cys  AAT → TGC 
189 Ser  → Cys TCG → TGC 
190 Thr  → Cys ACG → TGC 
191 Leu  → Cys CTC → TGC 
192 Pro  → Cys CCG → TGC 
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Figure 4.1. Expression of ECL2 single cysteine mutants. Expression analysis of HA-
CYS¯AT1R (lane 2) and HA-tagged single cysteine mutants (lanes 3-22) in transiently 
transfected COS1 cells. Untransfected cells served as negative control (lane 1). ~42 kDa 
band corresponds to the fully-glycosylated mature cell surface receptor. The multimeric 
receptor bands are observed between 50-80 kDa. Actin expression levels are shown as 
loading control.  
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Figure 4.2. The expression analysis of Ile177 and Val179 mutants with cysteine, 
alanine and serine substitutions. 
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be important to define the structural context for Cys181 to form the disulfide with Cys101. 
Non-tolerated mutations at these positions may change the stability of this disulfide bond 
and the proper folding of the TM helices by increasing the energy of folding due to the 
nature and orientation of the substituted side chain. The introduced cysteine side chain at 
position 179 might directly interfere with the formation of the Cys101-Cys180 disulfide 
bond or induce the formation of an abnormal disulfide bond resulting in an unstable 
receptor polypeptide.  
 
4.3 Effect of Cysteine Substitutions in ECL2 
The cell surface receptor expression (Bmax) of twenty single cysteine mutants 
measured in intact COS1 cells is shown in Table IV.II. Bmax values of mutants T178C, 
H183C, R187C, N188C and L191C was within 5-fold and <20-fold for the remaining 
mutants. The calculated cell surface receptor number shows that there are enough 
receptors on the cell surface to perform RCAM analysis in mutants with lower Bmax 
values, I177C, V179C, E185C and P192C. The calculated fold changes in Kd values for 
mutants compared to HA¯CYS-AT1R suggested that all mutants bound the ligand with 
high-affinity and specificity (Table IV.II). Binding of agonist Ang II elicited ERK1/2 
activation response in all ECL2 mutants, demonstrating the capacity of mutants to 
assume active conformation (Table IV.II). Ang II-induced ERK1/2 activation capacity 
displayed by mutants E173C, T175C, E185C, S186C, S189C is reduced compared to 
HA-CYS¯AT1R, however the reduction is not statistically significant (Table IV.II). The 
antagonist losartan inhibited Ang II-dependent activation of all mutants.  
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Table IV.II. Characterization of ECL2 single cysteine mutants. 
 
Cell Surface Expression 
ΔKd** MAPK activation*** 
Bmax (mean±SEM)     ~Receptors/cell* 
HA-CYS¯AT1R 5.80 ± 0.12 350,000 1.0 Yes 
I172C 0.36 ± 0.07 21,500 1.3 Yes, p = 0.20 
E173C 0.34 ± 0.03 20,600 1.4 Yes, p = 0.44 
N174C 0.66 ± 0.05 40,000 1.4 Yes, p = 0.69 
T175C 0.72 ± 0.01 43,000 1.4 Yes, p = 0.69 
N176C 0.71 ± 0.12 43,000 1.3 Yes, p = 0.35 
I177C 0.26 ± 0.05 15,800 1.3 Yes, p = 0.88 
T178C 2.32 ± 0.32 139,600 1.6 Yes, p = 0.79 
V179C 0.12 ± 0.02 7,500 2.3 Yes, p = 0.39 
A181C 0.38 ± 0.03 22,700 2.1 Yes, p = 0.60 
F182C 0.71 ± 0.11 42,800 1.4 Yes, p = 0.34 
H183C 1.94 ± 0.47 116,700 1.4 Yes, p = 0.66 
Y184C 0.34 ± 0.04 20,600 1.8 Yes, p = 0.54 
E185C 0.11 ± 0.03 6,700 2.3 Yes, p = 0.51 
S186C 0.91 ± 0.32 55,100 1.9 Yes, p = 0.55 
R187C 6.50 ± 0.20 391,700 1.6 Yes, p = 0.51 
N188C 3.36 ± 0.21 202,600 1.4 Yes, p = 0.35 
S189C 0.78 ± 0.05 46,700 2.1 Yes, p = 0.69 
T190C 0.61 ± 0.05  36,800  1.9 Yes, p = 0.98 
L191C 1.59 ± 0.23 95,600 2.2 Yes, p = 0.90 
P192C 0.03 ± 0.01 1,700 3.0 Yes, p = 0.68 
HA-AT1R 3.5 ± 0.15  175,000 0.8 Yes, p = 0.65 
 
    * Number of receptors on the cell surface calculated by the formula: [(Bmax*Avogadro’s 
number) / number of cells].  
  ** Kd value for HA-CYS ¯AT1R is 4.4 nM. Kd value for HA-AT1R is 3.5 nM. 
  *** MAPK activation indicates that ERK is phosphorylated upon treatment with 1µM Ang II, 
demonstrating the ability of mutants to assume active conformation upon binding Ang II. P-
values are derived from two-tailed, unpaired t-test. 
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The results presented in this chapter suggest that, the single cysteine substitution 
in the ECL2 region did not cause gross defect in the conformation which indicates that 
substituted cysteine residue orientation is similar to that of the wild type residue at each 
position.  
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CHAPTER V 
ACCESSIBILITY MAPPING ANALYSIS OF ECL2 
 
5.1 Introduction 
Variations of the site-directed cysteine labeling (modification) techniques have 
been a very a powerful approach in structure-function studies of GPCRs. Site-directed 
cysteine residues are used as sites for attachment of spin-label reporter groups (Loewen et 
al, 2001), for binding metal ions or for inducing site-specific cross linking (Itoh et al, 
2001, Cai et al, 2001) to unravel structural and dynamic features of functional motifs in 
rhodopsin and other neuroendocrine GPCRs. Site-directed spin labeling studies pioneered 
by Hubbell and Khorana (Farrens et al, 1996, Altenbach et al, 1996) employed site-
directed cysteine substitutions to analyze the folding and conformational dynamics. 
Specific positions in receptors can be labeled with 13C-methyl to facilitate structural 
analysis by nuclear magnetic resonance (NMR) spectroscopy (Bokoch et al, 2010). 
Sulfhydryl groups can be modified with specific reagents such as 2-nitrobenzoic acid 
(DTNB) that enable spectrophotometric monitoring of the reaction (Yang et al, 1996). 
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Methanethiosulfanate (MTS) reagents are more recently described thiol-specific 
probes, which provide advantages due to their high selectivity and rapid reactivity with 
the thiolate anion (S—) rather than the reduced -SH (Akabas et al, 1992). Only water 
accessible cysteines ionize to thiolate and thus react with hydrophilic MTS reagents a 
billion times faster than buried cysteines, which cannot ionize to a significant extent 
(Roberts et al, 1986). Thus, rapid MTS-reactivity indicates location of a cysteine in the 
water-accessible regions of a protein. A cysteine group facing the membrane or the 
protein interior would not react or react poorly. The influence of MTS-reacted cysteines 
on ligand binding is a measure of accessibility of a reporter cysteine in the ligand binding 
pocket. The criterion for identifying an accessible reporter cysteine is the inhibition of 
ligand binding due to the reaction with the MTS reagent. In addition, the residue is 
identified as a part of the ligand binding pocket if the MTS reaction is retarded in the 
presence of agonists or antagonists. If a position does not tolerate cysteine substitution 
due to its role in protein stability, folding or ligand binding, its accessibility can be 
inferred from neighboring reporters. Thus, exposure of site-directed cysteines, found in 
the water-exposed surface and in the aqueous pockets, or channels, within the TM 
proteins can be very rapidly and accurately measured by MTS reagents in situ, in the 
native membrane environment, without purifying the protein to a homogenous 
preparation.  
 
Reporter cysteine accessibility mapping methodology was previously used to 
determine activation-induced conformational changes in the TM helices of AT1R (Miura 
et al, 2002, Miura et al, 2003, Boucard et al, 2003, Martin et al, 2007, Yasuda et al, 2008, 
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Domazet et al, 2009). In these studies, the reaction rate and the degree of modification of 
substituted cysteines by MTS reagents, measured by radioligand binding, was used to 
infer dynamic changes in specific TM helices. However, the indirect measurement of 
MTS-reactivity with a reporter cysteine has limitations. False negative results are 
possible, since a reporter may be accessible, but ligand binding may not be inhibited by 
its reaction with MTS reagent. If a residue is covered by ligand upon treatment, its 
reactivity can not be determined.  
 
We developed a new probing method which overcomes some of these limitations 
in the current study. Using MTSEA-biotin (N-biotinylaminoethylmethanethiosulfonate) 
reaction, followed by streptavidin-HRP detection (Fig. 3.6), we could directly analyze the 
degree of modification of reporter cysteines. Figure 5.1 explains the principle behind the 
MTSEA-biotin labeling strategy. This procedure can be performed both in the absence 
and presence of the ligand. It allows us to get a direct readout for every position in 
different ligand-bound states of the receptor.   
 
In this chapter, the MTSEA-biotin accessibility of single cysteine mutants of 
ECL2 was compared in different ligand-bound states; empty, agonist-bound and 
antagonist-bound states. The reactivity of HA-CYS¯AT1R to MTSEA-biotin is 
considered as baseline to identify a residue as accessible or inaccessible (Fig. 3.6). Any 
significant measurement above the reactivity of HA-CYS¯AT1R indicates accessibility 
of the particular reporter cysteine.  The receptor topology was preserved during MTSEA-
biotin reaction as closely as possible to the native state in the plasma membrane by using 
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Figure 5.1. MTSEA-biotin labeling of accessible cysteine reporters. Schematic 
explanation of principle behind MTSEA-biotin labeling strategy. MTSEA-biotin 
preferentially reacts with water-accessible cysteines and does not react with buried or 
disulfide bonded cysteines. The reaction of MTSEA-biotin with thiol group of an 
accessible cysteine can be detected by Streptavidin-HRP.   
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adherent cells rather than fractionated membranes. This analysis allowed us to deduce the 
conformational changes of ECL2 associated with AT1R activation/inhibition. 
 
5.2 Experimental Set Up for Accessibility Mapping 
Intact COS1 cells expressing each of the reporter cysteine mutants were exposed 
with 10 mM MTSEA-biotin for 30 min at room temperature (23 °C). We did not use >10 
mM concentration for reasons of cost of the MTSEA-biotin reagent. Carrying out the 
reaction at room temperature was necessary to minimize spontaneous and ligand-induced 
receptor internalization. 20-30% of AT1R internalize spontaneously at 37 °C in 60 min. 
Ang II induces internalization of >80% of AT1R at 37°C in 60 min. At room 
temperature, Ang II-induced internalization of AT1R is <10% in 30 min. Under these 
conditions, we were able to obtain optimal cysteine-biotinylation in AT1R without 
affecting the integrity of cells (Fig. 5.2). As previously described in Section 3.4, the 
modification levels of single cysteine mutants of ECL2 were determined by normalizing 
the streptavidin-HRP signal of immunoprecipitated receptors to the HA signal. The 
streptavidin-HRP signal of the HA-CYS¯AT1R was used as the control. The relative 
MTSEA-biotin accessibility of a mutant was calculated as the ratio of streptavidin-HRP 
signal for that mutant to the same signal for HA-CYS¯AT1R in the same experiment. 
This control minimizes confounding factors which might influence the readout due to 
different cell surface expression levels. Fully glycosylated monomeric receptor band was 
monitored for the mapping studies. As seen in Table V.I, examination of monomeric 
band yields more consistent results with lower standard error compared to multimeric 
band. The overall accessibility pattern was same regardless of whether the monomeric or 
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Figure 5.2. Optimization of MTSEA-biotin reaction conditions. A) Concentration 
dependence of streptavidin-HRP signal. B) Time course analysis of Streptavidin-HRP 
signal upon treatment with 10 mM MTSEA-biotin. 
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Table V.I. Comparison of MTSEA-biotin reactivity of fully-glycosylated monomeric 
receptor and multimeric forms of the receptor.  
 
 41.9 kDa Monomeric form Relative Accessibility  
50-80 kDa Multimeric 
Relative Accessibility  
Mutants Mean S.E.M. Mean S.E.M. 
HA-CYS¯AT1R 1.00 0.24 1.00 0.28 
I172C 1.39 0.40 1.04 0.24 
E173C 1.86 0.48 1.53 0.79 
N174C 3.08 0.60 1.52 1.21 
T175C 3.18 0.49 1.24 0.97 
N176C 1.61 0.06 1.07 0.35 
I177C 0.58 0.17 1.31 0.38 
T178C 1.63 0.09 1.16 0.26 
V179C 0.73 0.16 0.94 0.10 
A181C 0.01 0.01 0.84 0.21 
F182C 0.81 0.20 0.83 0.42 
H183C 0.42 0.06 0.88 0.32 
Y184C 1.04 0.17 1.56 1.04 
E185C 2.03 0.56 1.67 0.62 
S186C 2.38 0.47 1.91 1.46 
R187C 3.52 0.23 1.29 0.92 
N188C 0.57 0.15 0.55 0.13 
S189C 2.08 0.28 1.56 1.43 
T190C 1.57 0.34 0.90 0.17 
L191C 0.92 0.20 0.97 0.75 
P192C 1.21 0.23 0.99 0.96 
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the multimeric bands were analyzed. 
               
The binding of agonist (Ang II) and antagonist (losartan) caused changes in the 
reactivity of two representative cysteine reporters, replacing His183 and Glu185. The 
H183C did not react in the absence of ligand (Fig. 5.3 A) but reacted very well in the Ang 
II-bound state (Fig. 5.3 B). In contrast, Ang II binding rendered E185C less reactive, 
although it was highly reactive in the absence of Ang II. In the presence of the antagonist 
losartan, the reactivity of both cysteine reporters was reduced. These results provided the 
first indication that the binding of agonists and antagonists induce distinct changes in the 
conformation or position of ECL2 in AT1R. Differential labeling of a particular mutant 
with and without agonist/antagonist suggests that the binding of ligand influences the 
position/conformation of ECL2 and alters accessibility of the reporter.  
 
In the empty-state, the observed MTSEA-biotin reactivity for H183C was 
significantly lower compared to HA-CYS¯AT1R (Fig. 5.3 B), which has no free 
cysteines. The reasons for lower reactivity of H183C and several other mutants are not 
clear at this time. Theoretically, the MTSEA- biotin reaction for substituted cysteine 
should be greater than or at least equal to HA-CYS¯AT1R. The observed discrepancy is 
not correlated with the level of expression of H183C or other mutants and potential 
masking of other cysteines in the basal conformation. Since Ang II or losartan binding 
was able to change the H183C reactivity (Fig. 5.3 B), the substituted cysteine at this  
position was acceptable as a sensor of local conformational change. We apply the same 
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Figure 5.3. MTSEA-biotin accessibility of representative mutants. A) 
Immunoprecipitated receptors were probed for HA (left) and Streptavidin-HRP (right) to 
detect receptor expression and biotinylation levels respectively. The same blot was used 
for probing with HA and Streptavidin-HRP. The blots for representative mutants H183C 
and E185C are shown under three experimental conditions; in the absence of ligand 
(upper), in the presence of 1 μM Ang II (middle) and in the presence of μM losartan 
(lower). The fully glycosylated monomeric receptor band at 41.9 kDa was used for 
determination of MTSEA-biotin accessibility. HA signal intensity and streptavidin-HRP 
signal intensity of each sample was compared to the HA-CYS¯AT1R in the same gel as 
indicated by numbers below the bands. The corresponding plots show the MTSEA-biotin 
relative accessibility, which is the ratio of relative Streptavidin-HRP signal to relative HA 
signal for particular sample. Relative MTSEA-biotin accessibility of each mutant was 
compared to the HA-CYS¯AT1R in the same gel. Inset is the schematic representation of 
reporter cysteines which point up when inaccessible and point down when accessible, 
reacted with MTSEA-biotin (shown as -SR in red).  
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consideration for other mutants. 
 
5.3 Accessibility of ECL2 in the Absence of Ligand 
The accessibility level of each single cysteine mutant was determined in 
comparison to the HA-CYS¯AT1R control. The accessibility map of cysteine reporters in 
ECL2 without ligand is shown in Figure 5.4 A. The mean ± S.E.M. observed for HA-
CYS¯AT1R in nine independent experiments represents the streptavidin-HRP signal for 
the receptor that lacks free cysteine residues. The red bar indicates the cut off value 
below which the measurement is considered inaccessible. Significantly higher 
streptavidin-HRP signal (mean ± S.E.M.) was observed for reporter cysteines residues in 
two distinct regions of ECL2. The accessible N-terminal (Glu173, Asn174, Thr175, Asn176 
and Thr178) and the C-terminal (Glu185, Ser186, Arg187, Ser189 and Thr190) regions were 
separated by a region of low MTSEA-biotin reactivity. The inaccessible Ile177-Tyr184 
segment contains at its center the highly conserved disulfide bond linking ECL2 to 
TMIII. In addition, reporter cysteine residues at Ile172, Ile177, Asn188, Leu191 and Pro192 
were also inaccessible. All of the mutants in which MTSEA-biotin labeling did not 
increase, were expressed on the cell surface (Table IV.II) and efficiently 
immunoprecipitated as shown by the HA blot, suggesting that the absence of signal was 
due to the inaccessibility of the particular cysteine reporter, and not due to the lack of cell 
surface expression. Unlabeled receptors with reduced cell surface expression levels 
(I177C, P192C) were still present at sufficient quantity to yield accessibility signal, as 
seen upon ligand exposure (see section 4.3). 
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Figure 5.4. MTSEA-biotin accessibility maps of ECL2 single cysteine mutants. The 
MTSEA-biotin relative accessibility of mutants are expressed as mean ± S.E.M., n=3. 
Red line shown on graph designates the significance cut off (S.E.M. of HA-CYS¯AT1R 
accessibility, n=9) that determines the accessibility of mutants. Mutants with significantly 
higher accessibility compared to HA-CYS¯AT1R are indicated with red asterisk. The 
conserved Cys180 residue is marked by gold star. A) MTSEA-biotin accessibility map of 
ECL2 mutants in the absence of ligand. The autoantibody binding epitope sequences are 
indicated in dark red. B) MTSEA-biotin accessibility map of ECL2 mutants in the 
presence of AngII. C) MTSEA-biotin accessibility map of ECL2 in the presence of 
losartan.  
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5.4 Accessibility of ECL2 Upon Ang II Binding 
Surprisingly, Ang II treatment prior to MTSEA-biotin reaction significantly 
reduced the overall accessibility of ECL2 (Fig. 5.4 B). Residues Glu173, Asn174, Thr175, 
Asn176 and Thr178, Glu185, Ser186, Arg187 and Thr190 which were found to be highly 
reactive in the absence of ligand did not react in the presence of Ang II. The protection of 
residues by Ang II implies two possibilities, either that Ang II masked these residues 
directly or that ECL2 undergoes an Ang II-dependent conformational change. The pattern 
of accessibility throughout the ECL2 residues clearly indicates that blocks of residues 
show similar accessibility patterns rather than individual ones. Decreased accessibility of 
consecutive residues of ECL2 in two segments rather than individual residues supports 
the idea that Ang II induces conformational rearrangement of ECL2. Ang II binding 
increased the accessibility of Ala181, Phe182 and His183, which are immediately C-terminal 
to the disulfide bonded Cys180. Thus, the Ang II-induced change is consistent with 
increase in local conformational entropy involving the disulfide bond. 
 
5.5 Accessibility of ECL2 Upon Losartan Binding 
The presence of AT1R-selective antagonist, losartan, during the MTSEA-biotin 
labeling (Fig. 5.4 C) also decreased the overall reactivity of ECL2 similar to Ang II-
bound state. These accessibility changes in the presence of antagonist are similar to that 
observed in rhodopsin (Palczewski et al, 2000, Ahuja et al, 2009) and dopamine receptor 
(Shi et al, 2004) where ECL2 forms a cap over the inhibitor binding site.  
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However, losartan binding increased the reactivity of residues in the Asn176-Val179 
region, which are immediately N-terminal to the disulfide bonded Cys180. Thus, losartan 
binding induced flexibility on the other side of the disulfide bond compared to Ang II 
bound-state. Thus, conformational changes induced near the disulfide bond upon binding 
of the agonist are different from those induced by binding of the antagonist. These results 
suggest that ECL2 adopts different conformations in Ang II- and losartan-bound states. 
 
5.6 Rate of Change in MTSEA-biotin Accessibility 
The observation that the accessibility of residues on either side of the disulfide 
bond-tether of ECL2 changes upon ligand binding raised an important question: Do the 
induced conformational changes indicate a flexible or rigid-body motion of ECL2? Does 
the conformation of ECL2 change as a single entity or do different segments (residues) of 
ECL2 have different rates of accessibility changes?  
 
We determined the rate of accessibility change for two representative reporter 
cysteines in ECL2, on each side of the disulfide-tether. The reactivity of MTSEA-biotin 
was measured following 0 min, 2 min, 5 min and 10 min treatment with Ang II. The 
accessibility of N174C reporter decreased in the presence of Ang II, with a slope of 0.298 
which suggested a gradual conformational change for this residue (Fig. 5.5 A). On the 
other hand, the accessibility of F182C reporter increased in the presence of Ang II, with a 
slope of 0.058. The slower rate observed for Phe182 residue compared to Asn174 might be 
due to the fact that Phe182 residue is closer to the disulfide bond which might have 
restricted its flexibility to some extent compared to a residue far from the disulfide bond 
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restriction. The result indicates that the two segments in ECL2 have different rates of 
accessibility changes (Fig. 5.5 B). This observation suggested that ECL2 does not change 
its conformation as a single entity; instead, two regions undergo conformational changes 
independently from each other.  
 
ECL2 is highly accessible in the absence of any ligand. Agonist and antagonist 
binding differentially alters the accessibility of ECL2 leading to distinct conformations in 
two different ligand-bound states. The data suggests that ECL2 is a flexible region as 
predicted by theoretical models. Tethering ECL2 to TMIII via the conserved disulfide 
bond is an important structural constraint, giving different flexibility to two segments of 
ECL2, which allows ECL2 to follow different folding depending upon the nature of the 
ligand. A ligand-specific conformational change of ECL2 may be associated with the 
activation/inhibition of AT1R. 
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Figure 5.5. Rate of change in MTSEA-biotin accessibility for representative 
mutants. A) Rate of change in MTSEA-biotin accessibility for N174C mutant. 
Experiment was performed by treating cells with 1µM Ang II for 0 min, 2 min, 5 min and 
10 min. The relative accessibility to 20 mM MTSEA-biotin was measured as described 
before. Inset shows the linear trend line and the equation.  B) Rate of change in MTSEA-
biotin accessibility for F182C mutant. Inset shows the trend line and the equation.   
A 
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CHAPTER VI 
INSIGHTS FROM MOLECULAR DYNAMICS (MD) SIMULATIONS 
 
6.1 Introduction 
As a computational approach, molecular dynamics (MD) simulations provide 
insights into the dynamic nature of biological molecules and their inherent motion as a 
function of time. It helps the interpretation of experimental data. We performed MD 
simulations using the accessibility constraints determined by MTSEA-biotin labeling 
(Fig. 5.3) to predict the conformation of the ECL2. MD simulations were performed 
using model structures of AT1R (PDB ID: 2AC6) and AT1R with Ang II (PDB ID: 
2AH3) as explained in Figure 2.10. The ECL2 simulation in the presence of losartan was 
performed on a de novo AT1R model docked with losartan. Together, these studies 
provide a greater insight into the functional role of dynamic motions in ECL2 and 
improve our understanding of AT1R interaction with Ang II, losartan and auto-
antibodies.  
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6.2 Overall Approach 
MD simulation on empty, Ang II-bound and losartan-bound models was 
performed as explained in Figure 2.10. In each instance, 100 frames were obtained at the 
end of 14 ns simulation. To illustrate the strategy, all 100 frames for the empty state of 
the receptor are shown in Figure 6.1 as an example. The overall backbone conformation 
of ECL2 in each frame is examined for conformity with the experimental results obtained 
using MTSEA-biotin accessibility mapping of the ECL2 in the empty state of the 
receptor. Among several frames which displayed an ECL2 conformation concordant with 
the experimental data, we chose the frame number 1 (Figure 6.2 A) for the empty state of 
the receptor. When the side chains of the ECL2 region were added (Figure 6.2 B) and 
energy minimization was carried out, the final orientation of every side-chain matched 
the accessibility data for this frame.  The same analysis was done for the Ang II- and 
losartan-bound states.  
 
6.3 MD Simulation of ECL2 in the Absence of Ligand 
The MD simulation in the absence of any ligand indicated that ECL2 
conformation is open toward the extracellular space (Fig. 6.2). The accessible residues on 
the N-terminal (Glu173, Asn174, Thr175, Asn176 and Thr178) and the C-terminal (Glu185, 
Ser186, Arg187, Ser189 and Thr190) regions of the ECL2 are shown in red color. The Val179 
to Tyr184 region harboring the conserved disulfide bond is deeper and more restricted than 
the N-terminal and C-terminal regions of the loop. Disulfide bonded cysteines, Cys101 and 
Cys180, are shown in yellow. The access to the ligand-binding pocket is wider near TMV-
TMVII, providing an open aqueous channel (see Chapter VII for discussion). 
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Figure 6.1. MD simulation of the ECL2 in the empty state of the receptor. A) The 
100 frames obtained from the MD simulation analysis of ECL2 in the empty state of the 
AT1R following 1000 steps of energy minimization using the backbone structure of 
AT1R model. (PDB ID: 2AC6) The ECL2 is shown in red. B) Superimposition of 100 
frames from the MD simulation analysis of ECL2 in the empty state of the AT1R. 
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A) 
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B) 
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Figure 6.2. The frame # 1 chosen for further analysis. A) Among the 100 frames, the 
frame #1 was chosen since the ECL2 conformation is consistent with the experimental 
results found by MTSEA-biotin accessibility mapping of ECL2 in the empty state of the 
AT1R. B) The side chains were then added to the ECL2 backbone. The disulfide bonded 
cysteines are shown in yellow. 
 
A                                                                  B 
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6.4 MD Simulation of ECL2 in the Presence of Ang II 
The MD simulation in the presence of Ang II depicts ECL2 forming a tightly 
packed lid against bound Ang II, which is shown in magenta in Figure 6.3. The accessible 
residues Ala181, Phe182 and His183 which are immediately C-terminal to the disulfide bond 
are shown in red.  
 
6.5 MD Simulation of ECL2 in the Presence of Losartan 
The MD simulation in the presence of losartan which is shown in blue in Figure 
6.4 also depicts a lid conformation of ECL2 similar to Ang II bound state of the receptor. 
The accessible residues, Asn176-Val179, which are immediately N-terminal to the highly 
conserved disulfide bond, are shown in red color. These results suggest that ECL2 adopts 
lid conformations in both Ang II- and losartan- bound states, but in a distinct orientation. 
Varying positions of the disulfide bond and the neighboring accessible residues in Ang 
II- and losartan-bound conformations of ECL2 indicates flexibility of the region that is 
normally thought to be constrained because of the disulfide bond. 
 
6.6 Analysis of Hydrogen Bonding Networks 
The overall decrease of ECL2 accessibility in the Ang II- and losartan-bound 
states compared to the empty state indicates that ECL2 conformation changes upon 
receptor activation. We used inaccessible residues as constraints to perform molecular 
dynamic simulation to gain insights on ECL2 conformational rearrangements. We 
analyzed the hydrogen bonding of the inaccessible residues in the empty, Ang II-bound, 
and losartan-bound states of the AT1R. To assign the rearrangement of hydrogen bonding           
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Figure 6.3. The frame # 48 chosen for further analysis. A) Among the 100 frames, the 
frame #48 was chosen since the ECL2 conformation is consistent with the experimental 
results found by MTSEA-biotin accessibility mapping of ECL2 in the Ang II-bound state 
of the AT1R. B) The side chains were then added to the ECL2 backbone. The disulfide 
bonded cysteines are shown in yellow. Ang II is shown in magenta. 
 
A                                                                     B 
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Figure 6.4. The frame # 39 chosen for further analysis. A) Among the 100 frames, the 
frame # 39 was chosen since the ECL2 conformation is consistent with the experimental 
results found by MTSEA-biotin accessibility mapping of ECL2 in the losartan-bound 
state of the AT1R. B) The side chains were then added to the ECL2 backbone. The 
disulfide bonded cysteines are shown in yellow. Losartan is shown in blue. 
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network in each receptor state, we simulated 3.2 Å hydrogen bond contacts of 
inaccessible ECL2 residues. In the empty state, ten inaccessible residues (Ile172, Ile177, 
Val179, Ala181, Phe182, His183, Tyr184, Asn188, Leu191 and Pro192) are involved in extensive 
interaction with TMII, TMIII, TMIV and TMV and ECL3 (red) (Fig. 6.5). A list of 
interactions in the absence of ligand is given in Table VI.I.  
 
In the Ang II-bound state, sixteen residues inaccessible to MTSEA-biotin (Ile172, 
Glu173, Asn174, Thr175, Asn176 Ile177, Thr178, Val179, Tyr184, Glu185, Ser186, Arg187, Asn188, 
Thr190, Leu191 and Pro192) increase intra-molecular contacts of ECL2 with TMI, TMII, 
TMIII, TMIV, TMV, TMVII and extra-cellular segments, N-terminal tail, ECL1 and 
ECL3 (red, Fig. 6.6). Two intermolecular hydrogen bonding networks; the first (green) 
between Ang II and TM-helices and the second (blue) between Ang II and ECL2 
highlights the major difference between basal and active states of AT1R. A list of 
interactions in the presence of Ang II is given in Table VI.II A and B. The N-terminal 
residues of Ang II are involved in interactions with TMIII and TMVII (green). The C-
terminal residues of Ang II are involved in interactions with N-terminal residues of ECL2 
(blue). 
 
The intra-molecular hydrogen bonding network in the presence of losartan is even 
more extensive including interactions with all TM helices (except TMI), N-terminal tail, 
ECL1 and ECL3, however these contacts are distinct compared to Ang II-bound state. 
The rearrangement of hydrogen bonding network in the inhibited receptor state upon  
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Figure 6.5. Hydrogen bonding network of ECL2 in the absence of ligand. A) 
Predicted intramolecular interactions of inaccessible residues of ECL2 with the TM 
helices in the absence of ligand are shown in red. TM helices are depicted as helical 
wheel diagram generated using Helical Wheel Projections 
(http://rzlab.ucr.edu/scripts/wheel/). Loop and extracellular residues are highlighted in 
yellow. B) Cartoon depiction of ECL2 interactions with TMD.  
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Table VI.I. Predicted interactions of inaccessible ECL2 residues with transmembrane residues in 
the absence of ligand. 
 
ECL2 TM interactions 
I172 Y170 
I177 T80, T88, L100, L81 
V179 F171, A104, C101, S105 
C180 V169, F171, Y170, Disulfide bond with C101 
A181 V169, N168 
F182 R167, H272, I271 
H183 L112, N168, V270, I271, H272, D273, C274 
Y184 S109, V108, I271, C274 
N188 S107, K199, H272, D273 
L191 H166, I165, V164, I193, G196, L195 
P192 G194, L195 
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Figure 6.6 Hydrogen bonding network of ECL2 in the presence of Ang II. A) 
Predicted intramolecular interactions of inaccessible residues of ECL2 with the TM 
helices in the presence of Ang II are shown in red. Two intermolecular hydrogen bonding 
network between Ang II and ECL2 (blue) and between Ang II and TM helices (green) are 
also shown. Loop and extracellular residues are highlighted in yellow. B) Cartoon 
depiction of ECL2 interactions with TMD (red), ECL2 interaction with Ang II (blue) and 
Ang II interactions with TMD (green). Ang II is shown in yellow. Three different 
hydrogen bonding networks stabilize the lid conformation. 
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Table VI.II  
A. Predicted interactions of inaccessible ECL2 residues with transmembrane residues in the 
presence of Ang II.  
 
ECL2 TM interactions 
I172  L100, Y170, W94, R93, C101 
E173 A89, Y92, R93 
N174 A104, Y170, F171, T88, C101 
T175 A89, A85, P82, T88, L81 
N176 I32, Y35, F31 
I177 I288, Y292 
T178  
V179  
C180 Y170, Disulfide bond with C101 
Y184 C274, H272, I271 
E185 Y170, F171, R13, I14 
S186 V169, R13, I14 
R187 F171, R13, K275, C274 
N188 A7, K12 
T190 I165, R167, V164, G196, L195, I271 
L191  
P192 G196, G194 
 
B. Predicted interactions of Ang II with transmembrane residues and ECL2. 
 
Ang II  TM interactions ECL2 interactions 
D1 L112   
R2 N111,A114,S115   
V3 N294,N295  
Y4 I290,A291,Y292,F293,N294,N295   
I5 S107,V108,S109 E173  
H6  I177,T178,V179 
P7  I172,T178 
F8 S109,Y113  
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losartan binding is shown in detail in Figure 6.7. The intermolecular hydrogen bonding 
network between TM helices and losartan (green) is less extensive than that between 
losartan and ECL2 (blue). A list of interactions in the presence of losartan is given in 
Table VI.III A and B. 
 
       Together, molecular dynamic simulation studies predict a flaccid ECL2 
conformation in the empty state. The ECL2 becomes more strongly hydrogen bonded in 
the ligand-bound state. Extensive intra-molecular hydrogen bonding network of ECL2 
with the TM helices, ECL1, ECL3 and N-terminal tail stabilizes a compact ‘lid’ like 
structure in both Ang II- and losartan-bound states. Two intermolecular hydrogen 
bonding networks between Ang II and TM helices and Ang II and ECL2 stabilize the 
agonist bound to the receptor. Individual contacts for the same ECL2 residues differ in 
agonist- and antagonist-bound states. Cooperatively, these hydrogen bonding networks 
may account for the experimentally found inaccessibility of ECL2 in the ligand-bound 
state and govern the high-affinity of AT1R towards Ang II and losartan and their rapid 
binding followed by slow dissociation (see chapter VI for discussion). Leaning of Ang II-
bound ECL2 towards one set of residues and losartan-bound ECL2 towards a different set 
appears to contribute respectively to receptor activation and inhibition. 
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Figure 6.7 Hydrogen bonding network of ECL2 in the presence of losartan. A) 
Predicted intramolecular interactions of inaccessible residues of ECL2 with the TM 
helices in the presence of losartan are shown in red. Two intermolecular hydrogen 
bonding network between losartan and ECL2 (blue) and between losartan and TM helices 
(green) are also shown. Loop and extracellular residues are highlighted in yellow. 1; 
imidazole ring, 2; phenyl ring 1, 3; phenyl ring 2, 4; tetrazole ring. B) Cartoon depiction 
of ECL2 interactions with TMD (red), ECL2 interaction with losartan (blue) and losartan 
interactions with TMD (green). Losartan is shown in cyan. Three different hydrogen 
bonding networks stabilize the lid conformation.  
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Table VI.III  
A. Predicted interactions of inaccessible ECL2 residues with transmembrane residues in the 
presence of losartan. 
ECL2 TM interactions 
I172 R13, I14, D17, D16, W84, W94, F96, L100 
E173 K12, R13, Q15, Y170, F171, A104, S107, V108, C101 
N174 P95, L81, P82 
T175 Y170, W94, A85 
C180 Y170, F171, Disulfide bond with C101 
A181 Y170 
F182 P285,M284 
H183 S107,I271,V270, T287,M284, S109 
Y184 S160, A106, H272, F259 
E185 H166, V164, V169 
S186 Y170, F171,V169 
R187 F171, V169, N168, H166, R167, Y170, F259 
N188 S109, V108, S105 
T190 V270, L195, G196 
L191 H272, L197, G196 
P192 L195, G196 
 
B. Predicted interactions of losartan with transmembrane residues and ECL2. 1; imidazole ring, 2; 
phenyl ring-1, 3; phenyl ring-2, 4; tetrazole ring. 
 
Losartan  TMD interactions ECL2 interactions 
1 H256,I288 A181,F182,H183,Y184,S186, R187,N188 
2 H256,T260 A181,H183,Y184, S186, N188,S189,T190 
3 Y113,K199,N200 S189,T190 
4 H256,Y113,Q257  
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CHAPTER VII 
DISCUSSION 
 
7.1 The Implications of Ligand Induced Conformational Change of ECL2 
Results presented here shed new light on ligand-specific structural dynamics of 
ECL2 in AT1R. In many peptide hormone GPCRs including AT1R, ECL2 directly 
interacts with agonists and is also a target of auto-antibodies. Hence the ligand-specific 
conformational dynamics of ECL2 in AT1R we describe here are insightful. 
 
An open conformation of ECL2 has been indicated by the accessibility 
measurements and molecular dynamics simulation of ECL2 in the empty state of the 
AT1R (Fig. 7.1 A). The open conformation of ECL2 may facilitate capture of ligands in 
AT1R by providing an aqueous channel to facilitate ligand entry and exit from the 
binding pocket in milliseconds (Bourne & Meng, 2000, Cherezov et al, 2007, Warne et 
al, 2008, Jaakola et al, 2008). As ligands enter the binding pocket through this aqueous 
channel, they may have transient interactions with the ECL2, an interpretation which is 
consistent with previous biochemical studies. Photoaffinity cross-linking studies have 
shown that Val3 in Ang II is cross-linked with Ile172 in ECL2 (Perodin et al, 2002). 
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Figure 7.1. Molecular dynamics simulation of ECL2. A) Molecular dynamics 
simulation of ECL2 in the absence of ligand. TMI, TMII, TMIII, TMVI and TMV are 
shown in cartoon model. The ECL2 residues and side chains are shown in stick and 
surface model. The accessible residues are shown in red. The disulfide bonded cysteines 
Cys101 (TMIII) and Cys180 (ECL2) are shaded in yellow. B) Molecular dynamics 
simulation of ECL2 in the presence of Ang II. Ang II is shown as magenta stick. The 
accessible residues are shown in red. C) Molecular dynamics simulation of ECL2 in the 
presence of losartan. Losartan is shown as blue stick. The accessible residues are shown 
in red. D) Zoomed view of ECL2 simulations in the empty, Ang II-bound and losartan-
bound states of the receptor. 
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Site-directed mutagenesis studies have shown that Ile172 and His183 in ECL2 specifically 
interact with Val3 and Asp1 side chains in Ang II, respectively (Feng et al, 1995, Boucard 
et al, 2000).  
 
The accessibility measurements and molecular dynamics simulation of ECL2 
indicated a “lid” conformation of ECL2 in the Ang II-bound state of the AT1R (Fig. 7.1 
B). Mutagenesis studies established direct interactions between TM helices II, III, V, VI 
& VII and Ang II. Photoaffinity cross-linking studies have shown that Phe293/Asn294 in 
TMVII interact with Phe8 of Ang II (Perodin et al, 2002). A molecular model of AT1R 
predicted that ligands bind in the TM domain ≈ 25 Å away from the membrane border 
(Gogonea et al, 2006). The model suggests that the N-terminal part of ECL2 dips into the 
binding pocket reaching the bound Ang II (Gogonea et al, 2006). Binding of Ang II may 
induce folding of ECL2 to an elaborate ‘lid’ conformation similar to that seen in the case 
of bovine rhodopsin (Fig. 5.3 B). This lid may interact with additional elements of the 
receptor's extracellular domain, i.e. ECL1, ECL3 and the NT. Thus, the ligand-induced 
folding of ECL2 requires considerable rearrangement of the hydrogen bonding networks 
in AT1R (Fig. 7.2).  
 
A similar “lid” conformation of ECL2 in the losartan-bound state of the AT1R is 
indicated by the accessibility measurements and molecular dynamics simulation of ECL2 
(Fig. 7.1 C). Mutagenesis, photoaffinity cross-linking and modeling studies (Boucard et 
al, 2000, Yamano et al, 1992, Noda et al, 1995, Schambye et al, 1994, Ji et al, 1994, 
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Figure 7.2. Predicted hydrogen bonding network formed by inaccessible residues of 
ECL2. The ECL2 is highlighted in dark grey. A) Intramolecular interactions of ECL2 
with the TM helices (red) in the absence of ligand. B) Intra-molecular interactions of 
ECL2 with the TM helices (red) in the presence of Ang II. Ang II is shown in yellow 
spheres. Two intermolecular hydrogen bonding network between Ang II and ECL2 (blue) 
and between Ang II and TM helices (green) are also shown. C) Intra-molecular 
interactions of ECL2 with the TM helices (red) in the presence of losartan. Losartan is 
shown in cyan spheres. Two intermolecular hydrogen bonding network between losartan 
and ECL2 (blue) and between losartan and TM helices (green) are also shown.  
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Nouet et al, 2000) show that losartan competitively occupies the Ang II binding site, 
implying that conformational rearrangement induced by losartan in another part of the 
receptor is not the cause of reporter Cys reactivity in ECL2. Molecular modeling studies 
show that the only mechanism for simultaneous ECL2 and TM domain interaction with 
losartan would be through folding of ECL2 into the pocket within the TM domain. 
Molecular dynamic simulation studies shown in Figure 5.3 C provide strong support for 
ECL2 forming a lid over losartan bound to the TM domain. Simulated interactions 
include direct contact between ECL2 and losartan and between ECL2 and TM-domain as 
well as ECL2 and other EC loops (Fig. 6.7). 
 
7.2 The Potential Role of Conserved Disulfide Bond 
Ligand-specific folding of ECL2 appears to induce specific perturbation around 
the disulfide bond, which may play a critical role in the inhibition and activation of the 
receptor. A distinct pattern of accessibility changes caused by losartan on the N-terminal 
side of the disulfide bond and by Ang II on the C-terminal side of the disulfide bond 
suggest that type of constraint experienced by the disulfide bond plays a critical role in 
the inhibition and activation of TM signaling, respectively.  
 
The N-terminal residues in Ang II interact with ECL2 and the C-terminus with the 
receptor’s inter-helical crevice, leading Ang II to fold into a ‘C’ shape, a conformation 
predicted in many studies (Marshall et al, 1974, Samanen et al, 1994, Garcia et al, 1992, 
Nikiforovich et al, 1994). Dynamics of ECL2 might be critical in the Ang II binding 
process, since three N-terminal residues in Ang II sequentially interact with Ile172, His183 
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in ECL2 and Asp281 in ECL3/TMVII, while the Ang II C-terminus inserts into receptor’s 
inter-helical crevice. The Ang II docking process may be completed, upon folding of the 
peptide ligand to a ‘C’ shape. We propose that ligand binding in AT1R leads to specific 
reorganization of the hydrogen bond network formed primarily with residues on ECL2, 
which is then coupled to the movements of TM helices involving the Cys101–Cys180 bond.  
 
The ECL2 length (27±13) is conserved in the GPCR family (Karnik et al, 2003), 
but the frequency of activating mutations targeting this region is lower than in the TM 
helices. Individual mutations in a flexible region of receptors may not relax the constraint 
for activation as readily as single residue mutations in TM helices. What is the 
significance of ligand-specific conformation of ECL2 in the receptor activation process? 
One possibility is that in the ligand bound state, the ECL2 interacts with multiple TM 
helices, which enables ECL2 to integrate conformational cues originating at multiple 
contacts between ligand and the receptor. In fact, the hydrogen bonding network analysis 
of ECL2 (Fig. 6.6) has shown that there is a considerable rearrangement of hydrogen 
bonding, increasing the number of contacts between ECL2 and TM domain. The disulfide 
bond located in the middle of ECL2 may be required for transmitting the conformation to 
TMIII. Conservation of the disulfide bond in >90% GPCR may indicate a general role for 
this bond in efficiently coupling ligand binding to GPCR activation. 
 
7.3 The Structural Basis for Binding of Autoantibodies 
The open conformation of the ECL2 in the empty receptor is independently 
supported by autoantibody epitope mapping studies in human AT1R (Liao et al, 2002, 
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Dragun et al, 2005, Zhou et al, 2008). Autoantibodies directed towards ECL2 in many 
GPCRs mimic the action of agonists, but their mechanism of action is unclear. 
Circulating autoantibodies recognize the readily accessible Ile172–Thr178 and Glu185–
Thr190 segments. For instance, agonistic autoantibodies from preeclampsia patients bind 
to the epitope ‘AFHYESQ’ (Zhou et al, 2008), and agonistic autoantibodies from patients 
with malignant hypertension and refractory, vascular allograft rejection bind to epitopes 
‘ENTNIT’ and ‘AFHYESQ’ in ECL2 (Liao et al, 2002, Dragun et al, 2005). It is 
interesting to note that the antigenic epitopes (dark red in Fig. 5.3 A) are interrupted by 
the Val179–Tyr184 region adjoining the disulfide bond that was found to be inaccessible by 
RCAM. Our analysis suggests that these autoantibodies can capture the accessible region 
and losartan could mask these epitopes to prevent such binding. Losartan binding, which 
masks epitopes, is known to protect patients harboring autoantibodies. 
 
In many other GPCRs the auto-antibodies directed towards ECL2 may also 
modulate the conformation of the EC-domain (Lebesgue et al, 1998, Wang et al, 2000). 
Autoantibodies directed against ECL2 regions were discovered in several human 
pathologies involving the muscarinic receptors, α1 and β1 adrenergic receptors and the 
bradykinin B2 receptor. In a more general sense, the conformational dynamics of ECL2 
may regulate the fundamental process of autoantibody-mediated activation and 
pathophysiological process involving GPCRs. Conformational display of epitopes in 
ECL2 may be the basis for allosteric activation of GPCRs by autoantibodies. 
Autoantibody binding to ECL2-epitopes may exert tension on the disulfide bond to 
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activate the AT1R directly or may open the entrance channel for circulating Ang II. Our 
findings might offer strategies for improved therapies. 
 
7.4 A Predicted Ang II-analogous pharmacophore in ECL2 
Of great interest, out of ten inaccessible residues in the empty state of the 
receptor, seven residues are similar to the residues in Ang II (Fig. 7.3), but their order is 
not the same as in Ang II. We speculate that the inaccessible residues of ECL2 may 
actually regulate low basal activity of ligand free receptor by presenting an Ang II-
analogous pharmacophore hidden within ECL2. Our RCAM analysis uncovered 
existence of this hidden pharmacophore, a set of structural features in ECL2 that might 
have a pharmacological effect on the receptor. Effect of the hidden pharmacophore in the 
empty receptor may be inhibitory. The hydrogen bonding network analysis of ECL2 in 
the absence of ligand (Fig. 6.5 A) has shown that some of the ECL2 interacting residues 
in TM domain are within the 3.2 Å of Ang II interacting residues (e. g. Lys199 is an Ang 
II binding residue). When the primary sequence of Ang II is scrambled, an inhibitory 
pharmacophore is generated as shown earlier (Marshall et al, 1974, Bumpus et al, 1977, 
Samanen et al, 1994, Miura et al, 1999). For instance exchanging residues at 4th, 6th and 
8th positions in Ang II converts the agonist to an antagonist, and lowers affinity for 
AT1R. Whether the predicted Ang II-analogous pharmacophore in ECL2 works like an 
extremely weak agonist or antagonist needs further study.  
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Figure 7.3. Ang II analogous ECL2 Pharmacophore. *The inaccessible residues of ECL2 in 
the empty-state which are similar to Ang II residues are shown. Three Ang II analogs  with 
different properties are also shown where the scrambled residues are indicated in bold italic.   
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7.5 The ECL2 of AT1R in context of GPCRs 
Previous studies in different GPCRs suggested that ECL2 is important for inactive 
receptor conformation and participates in ligand binding. Therefore, we evaluated the 
dynamic role of ECL2 in AT1R as the basis for complex functions attributed to it. Our 
RCAM results indicated that the ECL2 reacts with MTSEA-biotin with exception of the 
conserved disulfide bonded region. Binding of an agonist or antagonist limited solvent 
accessibility of most residues in ECL2, but the accessible residues differ in the presence  
of agonist and antagonist. These findings can be reconciled assuming that the ECL2 
undergoes specific ligand-induced conformational changes as a consequence of ligand-
receptor interaction. The conformational changes associated with TM and cytoplasmic 
domains of GPCRs during activation are conserved. We propose that specific kinetic and 
thermodynamic prerequisite for ligand and autoantibody recognition are achieved 
through conformational dynamics of ECL2. 
 
Structural changes in the ECL2 of GPCRs upon activation have been 
characterized for several GPCRs including rhodopsin and β-adrenergic receptors. In 
bovine rhodopsin, a compact ‘lid’ conformation of the extracellular domain which 
interacts with the inverse agonist form of the chromophore is documented (Bourne and 
Meng, 20005, Massotte et al, 2005, Palczewski et al, 2000, Park et al, 2008, Ahuja et al, 
2009). A less compact ‘lid’ conformation is maintained in opsin with an aqueous channel 
opening near the extracellular ends of TMV-TMVII and ECL3 (Park et al, 2008). NMR 
studies in light activated rhodopsin have shown the movement of ECL2 away from the 
activating ligand, all-trans-retinal. The ECL2 sequence of AT1R and rhodopsin share 11 
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of 21 residues (Fig. 7.4) and the predicted structures of ECL2 are ideally positioned to 
form multiple interactions with the bound ligand and other segments of the receptor 
(Gogonea et al, 2006). The ECL2 sequence of AT1R shows high propensity to form a β-
hairpin structure and a salt-bridge similar to rhodopsin. Direct interaction of Ang II 
possibly induces folding of ECL2 to a ‘lid’ conformation (Fig. 5.3 B), which is different 
when compared to the movement of ECL2 away from the activating ligand, all-trans-
retinal in light-activated rhodopsin (Ahuja et al, 2009). Considering the conformational 
changes in the TM domain, movements of TMIII, TMV, TMVI and TMVII have been 
shown to be critical for activation of both rhodopsin and AT1R. 
 
            Similar extracellular lids blocking the exit of bound inhibitory ligands are not 
found in the subsequently solved GPCR structures of β-adrenergic and adenosine 
receptors. Although tethered to TMIII, the ECL2 in these GPCRs is stabilized outside the 
ligand pocket by additional disulfide bonds (Cherezov et al, 2007, Warne et al, 2008, 
Jaakola et al, 2008). In the crystal structure of the β-adrenergic and adenosine receptors, 
ECL2 is not as extensively associated with the ligand binding pocket, leading to the 
speculation that absence of extracellular lid facilitates ligands’ entry and exit through the 
binding pocket in milliseconds. In rhodopsin-like peptide hormone receptors, 
significantly greater involvement of the ECLs in agonist interaction is documented 
(Karnik et al, 2003). What is the effect of reversible binding of diffusible ligands on the 
ECL2 conformation of peptide GPCRs? A recent solid-state NMR study on β2-
adrenergic receptor has shown that agonists induce a conformational change in ECL2 that 
differs from those induced by inverse agonists and an inward movement of ECL2 is 
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Figure 7.4. Alignment of ECL2 of AT1R with the ECL2 sequences of GPCRs for which 
crystal structures are available. The conserved cysteine is indicated by asterisk. The cysteines 
which are involved in disulfide bond formation in each GPCR is boxed in gold (1-7). The 
alignment was generated by using ClustalW2 (http://www.ebi.ac.uk/clustalw/).  
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associated with the active state of the β2-adrenergic receptor (Bokoch et al, 2010). 
 
In all five main human GPCR families (rhodopsin, glutamate, secretin, adhesion 
and frizzled/taste2), mutations targeting ECLs impair ligand dependent activation, also 
suggests a conserved function of the EC-domain throughout the GPCR superfamily 
(Karnik et al, 2003). Thus, the dynamic conformational changes in the ECL2 may be 
critical for the activation mechanism of the GPCRs. Mutations on the ECL2 led to 
constitutive activation in GPCRs such as TSH receptor and C5A receptor (Duprez et al, 
1997, Klco et al, 2005). ECL2 is a negative regulator of C5a receptor activation as 
discovered by genetic analysis. A similar role in stabilizing the inactive state in other 
GPCRs is proposed. In our study, none of the mutations caused constitutive activation 
and a previous genetic analysis also did not find mutations in ECL2 that cause activation 
of AT1R. ECL2 possibly serves an essential function in protein folding and maintaining 
the folded-state of the AT1R as indicated by I177C and V179C mutations. The 
susceptibility of folded AT1R to reducing agents is due to breaking the Cys101–Cys180 
disulfide linkage with TMIII (Ohyama et al, 1995, Feng et al, 2000). 
 
A rhodopsin-like ‘lid’ formed by ECL2 in the losartan-bound state is quite similar 
to the proposed arrangement of ECL2 in the D2 dopamine receptor in the antagonist 
bound state (Shi & Javitch, 2004). In other GPCRs the conformation of ECL2 in the 
presence of agonist is not reported. Similar conformational changes are likely in other 
GPCRs, where a direct role of ECL2 in ligand specificity is documented (Zhao et al, 
1996, Duprez et al, 1997, Banares et al, 2005). 
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Current ideas about how an extracellular lid may limit the access of ligands to 
cognate GPCRs are based on extrapolation from elegant dynamic and structural studies 
on bovine rhodopsin (Palczewski et al, 2000, Park et al, 2008, Ahuja et al, 2009). Our 
analysis allows us to reach a different conclusion, that a ‘lid’ conformation is induced in 
AT1R upon binding of both agonists and antagonists.  
 
7.6 Final Remarks 
The results of the current work provide explanation for several previous 
observations that remained unanswered. The open conformation of ECL2 provides an 
aqueous channel that facilitates access of ligands to the ligand binding pocket deep in the 
TM domain. As ligands enter the binding pocket through this aqueous channel, they may 
have primary interactions with the ECL2, an interpretation which is consistent with 
previous mutagenesis and cross-linking studies. The N-terminal residues in Ang II 
sequentially interact with Ile172 and His183 in ECL2, while the C-terminal residues in Ang 
II inserts into the binding crevice, interacting with TM residues (Gogonea et al, 2006). 
Photoaffinity cross-linking studies have shown that Val3 in Ang II is cross-linked with 
Ile172 in ECL2 (Perodin et al, 2002) and Phe293/Asn294 in TMVII interact with Phe8 of 
Ang II (Perodin et al, 2002), leading Ang II to fold into a ‘C’ shape, a conformation 
predicted in NMR studies (Marshall et al, 1974, Samanen et al, 1994, Garcia et al, 1992, 
Nikiforovich et al, 1994). The mechanism for simultaneous interaction of Ang II with 
ECL2 and TM domain can only be explained through folding of ECL2 into the pocket 
within the TM domain, as we have shown here. The Ang II docking process may be 
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achieved by specific rearrangement of the hydrogen bond network of ECL2, which is 
then coupled to the movements of TM helices involving the conserved disulfide bond.  
 
The open conformation of the ECL2 in the empty receptor is independently 
supported by autoantibody epitope mapping studies in human AT1R (Liao et al, 2002, 
Dragun et al, 2005, Zhou et al, 2008). Autoantibodies directed towards ECL2 of AT1R 
recognize the Ile172–Thr178 and Glu185–Thr190 segments, which are found to be readily 
accessible in our results. Our analysis suggests that these autoantibodies can capture the 
accessible region on the ECL2. It has been shown that, losartan binding could mask these 
epitopes to prevent autoantibody binding and protect patients harboring autoantibodies. 
The lid conformation of ECL2 induced by losartan suggests that the epitope regions are 
rendered inaccessible to autoantibodies, preventing their interaction with the AT1R. 
  
Transient formation of an EC-lid is most likely very important in GPCRs for 
blocking rapid exit of the ligand from the pocket. Their ligands bind to the pocket rapidly 
and leave the binding pocket at a much slower rate. For example, the dissociation rate (k-
a) is five times larger than the association rate (ka) of both Ang II and losartan for AT1R 
(Timmermans et al, 1993, Ojima et al, 1997). A transiently formed ‘lid’ can prevent the 
ligands from leaving the pocket rapidly, thus sustaining the ligand-specific conformation 
longer. In the agonist-bound state, this would allow the receptor to amplify the signal by 
prolonged G protein activation. Unlike rhodopsin, the activation in most other GPCRs 
may require different dynamic parts of the receptor to achieve a sharp transition to active 
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state. In this way, the ‘lid’ may help to ensure that the strain energy gain by agonist 
and/or antagonist binding is efficiently transformed into helix rearrangement. In other 
words, the ‘lid’ allows the ligand to flip the GPCR switch more easily and perhaps faster, 
as suggested by Bourne and Meng (2000). 
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CHAPTER VIII 
FUTURE WORK 
 
8.1 Introduction 
The results presented in this thesis have shown that binding of agonist and 
antagonist in AT1R induces formation of a distinct lid structure in ECL2, which closely 
interacts with the ligand. The specific conformations of the lid, particularly around the 
highly conserved disulfide bond that links ECL2 to TM III, were different in the Ang II-
bound and losartan-bound states. Are specific ECL2-lid conformations necessary for 
receptor activation and inhibition? Could ECL2 form a lid without the agonist, during 
constitutive activation of AT1R? How are the dynamics of ECL2 conformation affected 
by gain-of-function mutations located on TM-domain and loss-of-function mutations in 
the N-terminal tail and ECL3? Is the ECL2 conformation in mutant receptors similar to 
that of the empty-state or the ligand-bound state?      
 
Coordinated movement of different domains within a GPCR is critical for its 
biological function, transduction of signal across the membrane. Binding of a molecule to 
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the EC-domain initiates local conformational changes that involve several intermediate 
tates of dynamic movements within the protein. These dynamic movements take place in 
the nanosecond timescale, and lead to long-range rearrangements in the TM and 
cytoplasmic domains of GPCRs. Conformational changes also occur in the reverse order. 
For instance, G-protein binding to a GPCR initially changes the local conformation of the 
cytoplasmic loops, which subsequently propagates to the TM helices and the extracellular 
domains. Domain coupling has been shown to be critical for the biological activity of 
many different protein families with signaling and structural functions such as enzymes 
and receptors. However, the regulation of dynamic processes that facilitate domain 
coupling in proteins are poorly understood.  
 
The critical nature of domain coupling in transmembrane signaling by GPCRs is 
well documented. GPCRs exist in equilibrium between active and inactive conformations 
in the absence of any ligand. Different types of ligands stabilize distinct conformations. 
The inactive state of the receptor is stabilized by constraining intramolecular interactions; 
agonists release the constraints leading to coupling of the cytoplasmic domain to the G-
protein. Thus, agonist activation is associated with the initiation of the signal at the ligand 
binding site and the transmission of the signal along the transmembrane helices. Ligand 
induced rearrangement of helices consequently leads to structural changes on the 
cytoplasmic domain. On the other hand, antagonists and inverse agonists stabilize a more 
constrained inactive conformation that decreases the affinity towards the G-protein. 
Ligand-free GPCRs can also be driven to a high affinity state upon binding of G-protein 
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to the cytoplasmic face of the receptor which suggests that the conformational changes in 
the cytoplasmic domain are coupled to the conformation of the agonist binding site 
(Karnik et al, 2003). 
 
Gain-of-function, loss-of-function and misfolding mutants of GPCRs directly 
alter domain coupling between the extracellular, transmembrane and cytoplasmic 
domains of GPCRs (Karnik et al, 2003). Mutations that constitutively activate and 
increase the G-protein coupling efficiency of GPCRs also increases the affinity towards 
agonist by leading to a favorable reconfiguration at the agonist-binding site made up of 
extracellular and transmembrane domain residues. In contrast, mutations that impair 
agonist binding disrupt favorable interactions between the agonist and the binding pocket, 
thus keeping the cytoplasmic domain in a low-affinity state towards G-proteins. These 
observations suggest that a mutation in a particular domain of the receptor causes a local 
structural perturbation that can be transmitted to other domains leading to a global 
consequence in terms of affinity towards ligands and G-protein. 
 
Misfolding mutations of rhodopsin, known as retinitis pigmentosa (RP) 
mutations, have been extensively studied. These studies suggested that the cooperativity 
between different domains originated from the tertiary folding of the receptor 
polypeptide. (Spiegel, 1996, Berson, 1996, Hwa et al, 1997) RP mutations can also be 
located in the extracellular, transmembrane and cytoplasmic domains of rhodopsin and 
results in partially or completely misfolded receptors, suggesting that the coupling of 
tertiary structures of different domains take place during folding of the receptor 
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polypeptide. The misfolding of the receptor due to a RP mutation is usually associated 
with the loss of formation of the disulfide bond between TMIII and ECL3 of rhodopsin, 
which is conserved in more than 90% of GPCRs (Hwa et al, 1999 & 2001). This disulfide 
bond in rhodopsin is critical for generating the functionally active structure of the 
rhodopsin (Karnik et al, 1988). 
 
We propose that domain coupling is a central phenomenon of the GPCRs 
including AT1R (Karnik et al, 2003). The major structural evidence of domain coupling 
in GPCRs is the interhelical contacts in the TM domain. Intramolecular contacts, 
hydrophobic interactions and salt bridges between the extracellular domain and the TM 
domain indicate that the activity of TM domain is regulated by the structural features of 
the extracellular domain in GPCRs.  
 
Very little is known about the ligand-specific conformational changes in the 
extracellular domain and coupling of these movements to the TM domain. The results of 
this thesis project provide evidence for conformational coupling between the ECL2 and 
the ligand binding site, showing that different molecules targeting this region stabilize 
distinct conformations that would eventually affect the transmembrane and cytoplasmic 
domain conformation. In the AT1R model, ECL2 has been shown to have extensive 
contacts with the N-terminal tail, ECL3 and TM helices. (Fig. 8.1) Therefore we propose 
that the ECL2 conformation is influenced by mutations in the N-terminal tail, ECL3 and 
TM domain. Several residues on the N-terminal tail, ECL3 and TM domain of AT1R 
have been found to be important for both ligand binding and activation of the receptor. 
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What is the effect of specific residue mutations in these domains on the conformation of 
ECL2 in the absence and presence of different types of ligands? 
 
8.2 Experimental Design 
In order to determine the effects of structural changes in the other domains of the 
receptor on the ECL2 conformation, we will utilize the gain-of-function and the loss-of-
function mutants of AT1R. The conformational effects of these substitutions on the ECL2 
will be analyzed by measuring the accessibility of selected ECL2 residues in the presence 
of activating or inactivating substitutions, using the reporter cysteine accessibility 
mapping analysis with the same approach applied before.  
 
First, we want to analyze the effect of a gain-of-function substitution of Asn111 
residue, found on TMIII with glycine (Fig. 8.2). Asn111 residue interacts with the Tyr4 of 
Ang II (Feng et al, 1998) and is positioned close to the highly conserved disulfide bond 
that links TMIII to ECL2. Asn111 to Gly111 substitution leads to a constitutively active 
AT1R. The N111G-AT1R has been shown to have 50% more activity compared to wild 
type receptor (Feng et al, 1998). As the size of the substituted residue decreases, the basal 
IP3 production increases (Fig. 8.3). The N111G-AT1R showed higher affinity for Ang II 
and lower affinity for losartan (Fig. 8.3). Since N111G-AT1R mutants is constitutively 
activated, it is assumed to be in an active conformation. Is the conformation of ECL2 in 
N111G-CYS¯AT1R similar to that of the Ang II-bound state of CYS¯AT1R?  
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Figure 8.1. ECL2 interactions with NT, ECL3 and TM helices. A) Predicted 
interactions of NT (purple) with ECL1 (blue), ECL2 (green) and ECL (red). B) Predicted 
interaction of ECL2 (green) with ECL1 (blue) and ECL3 (red). C) Predicted interaction 
of ECL2 (green) with TM helices: TMI (purple), TMII (purple), TMIII (red), TMVII 
(blue). (Courtesy of Camelia Gogonea and S.Karnik)  
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Figure 8.2. The positions of substitutions to be analyzed. The substitutions selected to 
analyze are Arg23 on N-terminal tail, Asn111 on TMIII and Asp281 on ECL3, shown in red 
circles. These substitutions are combined with ECL2 reporter cysteines replacing Asn174, 
Asn176, Phe182 and Arg187, shown in pink circles. Cysteine residues substituted with 
alanine are shown in green circles. Cysteine residues involved in formation of disulfide 
bonds are shown in gold circles. 
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Figure 8.3. Characteristics of N111G-AT1R. A) IP production without agonist 
activation is measured as the percentage of IP produced by the same receptor when 
stimulated with 1 µM [Sar1] Ang II (100%) in parallel. Details are given by Miura et al, 
2002. B) The affinities of wild type AT1R and N111G-AT1R for Ang II and losartan. 
Details are given by Feng et al, 1998. 
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The other substitution that will be analyzed for its effects on ECL2 conformation 
is Arg23 to alanine substitution. Arg23 is located on the N-terminus of AT1R (Fig. 8.2). It 
interacts with Asp1 of Ang II. Its interaction with Asn176 of ECL2 has also been predicted 
(Gogonea & Karnik, 2006). The R23A-AT1R has been shown to have a reduced efficacy 
for Ang II (Santos et al, 2004). On the other hand it has a similar efficacy for losartan 
compared to wild type AT1R indicating that the mutation does not cause a gross defect in 
the receptor structure. Similarly, substitution of Asp281 to alanine also reduces the 
efficacy of the receptor towards Ang II, without changing the efficacy towards losartan 
(Hjorth et al, 1994, Feng et al, 1995, Costa-Neto et al, 2000, Santos et al, 2004). Asp281 
residue is located on the ECL3 and interacts with the Arg2 of Ang II (Fig. 8.2). Its 
interaction with Asn174 of ECL2 is also predicted (Gogonea & Karnik, 2006). Since these 
two substitutions result in loss-of-function mutants, they are assumed to be in a 
conformation that disfavors efficient binding of Ang II and accounts for a low-affinity 
state. Is the conformation of ECL2 in R23A-CYS¯AT1R and D281A-CYS¯AT1R 
similar to that of empty state or losartan-bound state of CYS¯AT1R? 
 
In order to determine the conformational effects of these substitutions on the 
ECL2, we will measure the accessibility of reporter cysteines replacing selected ECL2 
residues generated on the background of N111G-CYS¯AT1R, R23A-CYS¯AT1R and 
D281A-CYS¯AT1R. The selected ECL2 single cysteine mutants are N174C, N176C, 
F182C and R187C. These residues are shown to be highly sensitive to changes in the 
conformational state of the receptor based on our previously generated accessibility 
maps. The reasons for choosing these ECL2 residues for this analysis are listed below. 
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N174C:  
● close to Ile172 which is crosslinked to AngII 
● accessible in the absence of ligand and inaccessible in the presence of both AngII and 
losartan 
● in the autoantibody binding region 
 
N176C:  
● inaccessible in the absence of ligand, accessible in the presence of losartan 
● close to the disulfide bond 
● in the autoantibody binding region 
 
F182C:  
● inaccessible in the absence of ligand, accessible in the presence of AngII 
● close to the disulfide bond 
● in the autoantibody binding region 
 
R187C:  
● accessible in the absence of ligand, inaccessible in the presence of both AngII and 
losartan 
● in the autoantibody binding region 
 
The NIIIG mutation, R23A mutation and D281A mutation were simultaneously 
introduced into these single cysteine mutants by PCR mutagenesis as described in Figure 
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2.4. NIIIG-CYS¯AT1R mutant, R23A-CYS¯AT1R mutant and D281A-CYS¯AT1R 
mutant were also created for use as a control. The list of primers used in the PCR 
mutagenesis is provided in the Table VIII.I. The double mutants constructed for MTSEA-
biotin accessibility are listed in the Table VIII.II. All receptor mutants were confirmed by 
automated sequencing.  
 
Following construction of mutants, we started characterization of mutants. The 
expression analysis of N111G single cysteine mutants was performed by western blotting 
(Fig. 8.4). The expression patterns of all mutants were similar to HA-CYS¯AT1R, 
although there is a decrease in the expression. Further we analyzed the cell surface 
expression and binding affinities of N111G mutants by calculating Kd and Bmax values 
from scathchard plots (Table VIII.III). As expected we observed a higher affinity for 
[127I]-[Sar1Ile8] Ang II with the N111G single cysteine mutants compared to HA-
CYS¯AT1R. We also calculated the number of receptors on the cell surface to make sure 
that we have enough number of receptors on the cell surface especially for mutants with 
low Bmax values to perform accessibility analysis. The characterization of R23A and 
D281A mutants will be completed in the same way. The mutants will also be analyzed 
for their abilities to activate Ang II induced signaling pathway by Ca2+ transient 
measurements. After completion of characterization of mutants, we will determine the 
accessibility of mutants using the RCAM analysis with the same approach applied before 
in order to determine the conformational effects of these substitutions on the ECL2.  
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Table VIII.I. The list of primers used to generate N111G, R23A and D281A 
substitutions.  
PRIMER SEQUENCE bp %GC TM 
N111G sense GCCAGCGTGAGCTTCGGCCTCTACGCG 27 70.38 102.06 
N111G antisense CGCGTAGAGGCCGAAGCTCACGCTGGC 27 70.38 102.06 
R23A sense CCGAAGGCTGGAGCTCACAGTTAC 24 58.34 89.09 
R23A antisense GTAACTGTGAGCTCCAGCCTTCGG 24 58.34 89.09 
D281A sense GACATCGTGGCCACTGCCATGCCC 24 66.67 98.76 
D281A antisense GGGCATGGCAGTGGCCACGATGTC 24 66.67 98.76 
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Table VIII.II. List of double mutants. N111G-CYS¯AT1R, R23A-CYS¯AT1R and 
D281A-CYS¯AT1R are generated using HA-CYS¯AT1R background. The respective 
single cysteine mutants of ECL2 (available from the previous study) were used as 
templates to incorporate N111G, R23A and D281A substitutions simultaneously. All 
mutants have the HA epitope to facilitate analysis.  
 
N111G single cysteine mutants R23A single cysteine mutants D281A single cysteine mutants   
N111G-CYS¯AT1R R23A-CYS¯AT1R D281A-CYS¯AT1R 
N111G-N174C-CYS¯AT1R R23A-N174C-CYS¯AT1R D281A-N174C-CYS¯AT1R 
N111G-N176C-CYS¯AT1R R23A-N176C-CYS¯AT1R D281A-N176C-CYS¯AT1R 
N111G-F182C-CYS¯AT1R R23A-F182C-CYS¯AT1R D281A-F182C-CYS¯AT1R 
N111G-R187C-CYS¯AT1R R23A-R187C-CYS¯AT1R D281A-R187C-CYS¯AT1R 
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Figure 8.4. Expression of ECL2 single cysteine mutants with N111G mutation. 
Expression analysis of HA-CYS¯AT1R (lane 2) and HA-tagged single cysteine mutants 
with N111G substitution (lanes 3-7) in transiently transfected COS1 cells. Untransfected 
cells served as negative control (lane 1). Actin expression levels are shown as loading 
control. 
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Table VIII.III. Binding analysis of ECL2 single cysteine mutants with N111G 
mutation. The Kd value of HA-CYS¯AT1R was 5.10 nm and Bmax value was 7.46 
pmol/mg in the same experiment (n=3). *Number of receptors on the cell surface calculated 
by the formula: [(Bmax*Avogadro’s number) / number of cells].  
  
 
Mutant Kd (nm) ± S.E.M Bmax (pmol/mg) ± S.E.M ~Molecules/cell* 
N111G-CYS¯AT1R 1.21 ± 0.43 2.76 ± 0.63 166,211 
N111G-N174C 3.43 ± 0.20 0.78 ± 0.15 46,972 
N111G-N176C 1.15 ± 0.49 0.03 ± 0.01 1,806 
N111G-F182C 2.47 ± 0.38 0.39 ± 0.14 23,486 
N111G-R187C 2.45 ± 0.37 0.79 ± 0.12 47,574 
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